RespireRx Pharmaceuticals (RSPI) 10-Q15 Dec 142013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013
Document And Entity Information
Entity Registrant Name	CORTEX PHARMACEUTICALS INC/DE/
Entity Central Index Key	849636
Document Type	10-Q
Document Period End Date	30-Sep-13
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	144,041,556
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$10,039	$152,179
Deferred financing costs	23,301
Other current assets		17,002
Total current assets	33,340	169,181
Other		29,545
Total assets	33,340	198,726
Current liabilities:
Accounts payable and accrued expenses	1,787,000	1,509,827
Accrued compensation and related expenses	1,480,264	885,180
Notes payable to Chairman, including accrued interest of $18	40,018
Note payable to related party, including accrued interest of $61,719 and $25,340 at September 30, 2013 and December 31, 2012, respectively	498,277	465,392
Project advance, including accrued interest of $85,769 and $82,722 at September 30, 2013 and December 31, 2012, respectively	333,069	330,022
Total current liabilities	4,138,628	3,190,421
Commitments and contingencies (Note 11)
Stockholders' deficiency:
Common stock, $0.001 par value; shares authorized: 205,000,000; shares issued and outstanding: 144,041,556	144,041	144,041
Additional paid-in capital	125,188,620	125,183,892
Accumulated deficit	-129,459,652	-128,341,331
Total stockholders' deficiency	-4,105,288	-2,991,695
Total liabilities and stockholders' deficiency	33,340	198,726
Series B Convertible Preferred Stock [Member]
Stockholders' deficiency:
Preferred stock value	$21,703	$21,703

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accured interest to chairman	$18
Accrued interest	61,719	25,340
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	1,250,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	205,000,000	205,000,000
Common stock, shares issued	144,041,556	144,041,556
Common stock, shares outstanding	144,041,556	144,041,556
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation preference per share	$0.67	$0.67
Preferred stock, liquidation preference value	25,001	25,001
Preferred stock, shares authorized	37,500	37,500
Preferred stock, shares issued	37,500	37,500
Preferred stock, shares outstanding	37,500	37,500
Preferred stock shares issuable upon conversion, Per share	$0.10	$0.10
Preferred stock shares issuable upon conversion	3,679	3,679
Project Advance [Member]
Accrued interest	$85,769	$82,722

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Grant revenues				$48,309
Operating expenses:
General and administrative	29,575	389,398	893,342	1,715,236
Research and development	28,771	191,874	187,442	659,483
Pier merger-related costs		1,084,860		1,246,107
Gain on settlement of office lease			-1,990
Total operating expenses	58,346	1,666,132	1,078,794	3,620,826
Loss from operations	-58,346	-1,666,132	-1,078,794	-3,572,517
Interest income				91
Interest expense, including $12,277 and $93,550 to related parties for the three months ended September 30, 2013 and 2012, respectively, and $36,397 and $99,329 to related parties for the nine months ended September 30, 2013 and 2012, respectively	-13,304	-98,552	-43,021	-107,442
Foreign currency transaction gain (loss)	-29,515	-5,829	3,494	-16,249
Loss on sale of assets				-3,173
Net loss	($101,165)	($1,770,513)	($1,118,321)	($3,699,290)
Net loss per common share - Basic and diluted	$0	($0.02)	($0.01)	($0.04)
Weighted average common shares outstanding - Basic and diluted	144,041,556	118,007,496	144,041,556	96,497,067

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Interest expense to related parties	$12,277	$93,550	$36,397	$99,329

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Deficiency (Unaudited) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Balance		($2,991,695)
Related party short-swing trading profits of $11,500, net of legal costs of $6,772		4,728
Net loss	-101,165	-1,118,321	-7,572,244
Balance	-4,105,288	-4,105,288	-2,991,695
Series B Convertible Preferred Stock [Member]
Balance	21,703	21,703	21,703
Balance, shares	37,500	37,500	37,500
Common Stock [Member]
Balance	144,041	144,041	144,041
Balance, shares	144,041,556	144,041,556	144,041,556
Additional Paid-in Capital [Member]
Balance		125,183,892
Related party short-swing trading profits of $11,500, net of legal costs of $6,772		4,728
Balance	125,188,620	125,188,620
Accumulated Deficit [Member]
Balance		-128,341,331
Net loss		-1,118,321
Balance	($129,459,652)	($129,459,652)

Condensed_Consolidated_Stateme3

Condensed Consolidated Statement of Stockholders' Deficiency (Unaudited) (Parenthetical) (USD $)	9 Months Ended
	Sep. 30, 2013
Statement of Stockholders' Equity [Abstract]
Short-swing trading profits net	$11,500
Legal costs net	$6,772

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	($1,118,321)	($3,699,290)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		20,113
Amortization of license agreement		29,826
Gain on settlement of office lease	-1,990
Stock-based compensation costs		179,318
Pier merger-related costs paid in common stock options		310,000
Foreign currency transaction (gain) loss	-3,494	16,249
Amortization of capitalized financing costs		10,316
Amortization of discount on note payable		76,757
(Gain) loss on sales of assets		3,173
(Increase) decrease in -
Restricted cash		48,309
Other current assets	17,002	84,782
Other non-current assets	29,545	-20,656
Increase (decrease) in -
Accounts payable and accrued expenses	279,163	666,776
Accrued compensation and related expenses	595,084	578,877
Unearned revenue		-48,309
Deferred rent		-64,329
Accrued interest payable	39,444	18,296
Net cash used in operating activities	-163,567	-1,789,792
Cash flows from investing activities:
Cash acquired in connection with acquisition of Pier Pharmaceuticals, Inc.		23,208
Proceeds from sales of equipment		6,785
Purchases of furniture and equipment		-5,293
Net cash provided by investing activities		24,700
Cash flows from financing activities:
Related party short-swing trading profits	4,728
Proceeds from issuance of notes payable	40,000	399,774
Deferred financing costs related to Series G preferred stock	-23,301
Financing costs related to issuance of note payable		-21,370
Net cash provided by financing activities	21,427	378,404
Cash and cash equivalents:
Net decrease	-142,140	-1,386,688
Balance at beginning of period	152,179	1,610,945
Balance at end of period	10,039	224,257
Cash paid for -
Interest
Income taxes
Non-cash investing and financing activities:
Fair value of common stock issued in connection with acquisition of Pier Pharmaceuticals, Inc.		3,271,402
Fair value of warrant issued in connection with note payable		143,919
Write-off of fully-depreciated fixed assets		$834,016

Basis_of_Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation

	The condensed consolidated financial statements of Cortex Pharmaceuticals, Inc. (“Cortex”) and its wholly-owned subsidiary, Pier Pharmaceuticals, Inc. (“Pier”) (collectively referred to herein as the “Company”, unless the context indicates otherwise), at September 30, 2013 and for the three months and nine months ended September 30, 2013 and 2012, are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the consolidated financial position of the Company as of September 30, 2013, the results of its consolidated operations for the three months and nine months ended September 30, 2013 and 2012, and its consolidated cash flows for the nine months ended September 30, 2013 and 2012. Consolidated operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The condensed consolidated balance sheet at December 31, 2012 has been derived from the Company’s audited consolidated financial statements at such date.

	The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC.

Organization_and_Business_Oper

Organization and Business Operations	9 Months Ended
Organization and Business Operations	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	2. Organization and Business Operations

	Business

	Cortex was formed in 1987 to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. In 2011, prior management conducted a re-evaluation of Cortex’s strategic focus and determined that clinical development in the area of respiratory disorders, particularly respiratory depression and sleep apnea, provided the most cost-effective opportunities for potential rapid development and commercialization of Cortex’s compounds. Accordingly, Cortex narrowed its clinical focus at that time and abandoned other avenues of scientific inquiry. This re-evaluation provided the impetus for Cortex’s acquisition of Pier in August 2012 (see Note 4).

	On March 22, 2013, the Company received a written consent of stockholders holding a majority of the Company’s common stock signed by Origin Ventures II LP, Illinois Emerging Technologies Fund, LP, Illinois Ventures LLC, Samyang Optics Co. Ltd., Samyang Value Partners Co., Ltd., Steven Chizzik, Kenneth M. Cohen, Peter Letendre, David W. Carley and Aurora Capital LLC (the “Written Consent”) (i) removing Charles J. Casamento, M. Ross Johnson, John F. Benedik and Mark A. Varney from their positions as directors of the Company and (ii) appointing each of Arnold S. Lippa, Ph.D. and Jeff E. Margolis to fill two of the vacancies created, each to hold such office until the next annual meeting of the stockholders and until their successors have been duly elected and qualified. The Written Consent did not remove Moogak Hwang, Ph.D., a representative of Samyang Optics Co. Ltd., a lender to and significant stockholder of the Company (see Note 6), from the Board of Directors. Dr. Hwang continued to serve as a director until his resignation from the Board of Directors effective September 30, 2013 (see Note 6).

	Following the delivery of the Written Consent, the Board of Directors, acting by unanimous written consent dated March 22, 2013, removed all officers of the Company and appointed Dr. Lippa, as Chairman of the Board, President and Chief Executive Officer and Mr. Margolis, as Vice President, Treasurer and Secretary. On April 29, 2013, Robert N. Weingarten was appointed as a director, Vice President and Chief Financial Officer.

	Since new management’s appointment in March 2013, new management has continued to implement this revised strategic focus, including seeking the capital to fund such efforts. As a result of the Company’s scientific discoveries and the acquisition of strategic, exclusive license agreements (including a new license agreement with the University of Illinois, as described at Note 12), management believes that the Company is now a leader in the discovery and development of innovative pharmaceuticals for the treatment of respiratory disorders.

	Since its formation in 1987, Cortex has been engaged in the research and clinical development of a class of compounds referred to as ampakines. By acting as positive allosteric modulators of AMPA glutamate receptors, ampakines increase the excitatory effects of the neurotransmitter glutamate. Preclinical research suggested that these ampakines might have therapeutic potential for the treatment of certain respiratory disorders, as well as cognitive disorders, depression, attention deficit disorder and schizophrenia.

	In its early stages, Cortex entered into a series of license agreements in 1993 and 1998 with the University of California, Irvine (“UCI”) that granted Cortex proprietary rights to certain chemical compounds that acted as ampakines and their therapeutic uses. These agreements granted Cortex, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the license agreement, that were then held by UCI; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the license agreements, subject to the provisions of the license agreements. Cortex was required, among other terms and conditions, to pay UCI a license fee, royalties, patent costs and certain additional payments.

	At December 31, 2012, the Company was not in compliance with its minimum annual payment obligations and believed that this default constituted a termination of the license agreements. On April 15, 2013, UCI notified the Company that these license agreements were terminated due to the Company’s failure to make its obligatory payments. Since the patents covered in these license agreements had begun to expire and the therapeutic uses described in these patents were no longer germane to the Company’s new focus on respiratory disorders, the loss of these license agreements is not expected to have a material impact on the Company’s current or future drug development programs. In the opinion of management, the Company has made adequate provision for any liability relating to this matter in its financial statements at September 30, 2013.

	Cortex also owns patents and patent applications for certain families of chemical compounds, including ampakines, which claim the chemical structures and their use in the treatment of various disorders. These patents cover, among other compounds, Cortex’s lead ampakines CX 1739 and CX1942, and extend through at least 2028.

	On May 8, 2007, Cortex entered into a license agreement, as subsequently amended, with the University of Alberta granting Cortex exclusive rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. These patents, along with Cortex’s own patents claiming chemical structures, comprise Cortex’s principal intellectual property supporting Cortex’s research and clinical development program in the use of ampakines for the treatment of respiratory disorders. Cortex has completed pre-clinical studies indicating that several of its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opiates or certain anesthetics without offsetting the analgesic effects of the opiates or the anesthetic effects of the anesthetics. In two clinical Phase 2 studies, one of which was published in a peer-reviewed journal, CX717, a predecessor compound to CX1739 and CX1942, antagonized the respiratory depression produced by fentanyl, a potent narcotic, without affecting the analgesia produced by this drug. In addition, Cortex has conducted a Phase 2A clinical study in which patients with sleep apnea were administered CX1739, Cortex’s lead clinical compound. Preliminary results suggested that CX1739 might have use for the treatment of central and mixed sleep apnea, but not obstructive sleep apnea.

	In order to expand Cortex’s respiratory disorders program, the Company acquired 100% of the issued and outstanding equity securities of Pier effective August 10, 2012 pursuant to an Agreement and Plan of Merger (see Note 4). Pier was formed in June 2007 (under the name SteadySleep Rx Co.) as a clinical stage pharmaceutical company to develop a pharmacologic treatment for the respiratory disorder known as obstructive sleep apnea and had been engaged in research and clinical development activities since formation.

	Through the merger, the Company gained access to an Exclusive License Agreement, as amended (the “License Agreement”), that Pier had entered into with the University of Illinois on October 10, 2007. The License Agreement covered certain patents and patent applications in the United States and other countries claiming the use of certain compounds referred to as cannabinoids, of which dronabinol is a specific example, for the treatment of sleep related breathing disorders (including sleep apnea). Dronabinol is a synthetic derivative of the naturally occurring substance in the cannabis plant, otherwise known as Δ9-THC (Δ9-tetrahydrocannabinol). Pier’s business plan was to determine whether dronabinol would significantly improve subjective and objective clinical measures in patients with obstructive sleep apnea. In addition, Pier intended to evaluate the feasibility and comparative efficacy of a proprietary formulation of dronabinol.

	The License Agreement granted Pier, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the License Agreement, that were then held by the University of Illinois; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the License Agreement, subject to the provisions of the License Agreement. Pier was required under the License Agreement, among other terms and conditions, to pay the University of Illinois a license fee, royalties, patent costs and certain milestone payments.

	Prior to the merger, Pier conducted a 21 day, randomized, double-blind, placebo-controlled dose escalation Phase 2 clinical study in 22 patients with obstructive sleep apnea (“OSA”), in which dronabinol produced a statistically significant reduction in the Apnea-Hypopnea Index (“AHI”), the primary therapeutic end-point, and was observed to be safe and well tolerated. Dronabinol is currently under investigation, at the University of Illinois and other centers, in a potentially pivotal 120 patient, double-blind, placebo-controlled Phase 2B OSA clinical trial, fully funded by the National Institutes of Health.

	Dronabinol is a Schedule III, controlled generic drug with a relatively low abuse potential that is approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of AIDS-related anorexia and chemotherapy induced emesis. The use of dronabinol for the treatment of OSA is a novel indication for an already approved drug and, as such, the Company believes that it would only require approval by the FDA of a supplemental new drug application.

	The License Agreement was terminated effective March 21, 2013 due to the Company’s failure to make a required payment (see Note 5). New management subsequently opened negotiations with the University of Illinois, as a result of which the Company ultimately entered into a new license agreement with the University of Illinois on June 27, 2014, the material terms of which were similar to the License Agreement that had been terminated on March 21, 2013 (see Note 12).

	Going Concern

	The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses of $1,118,321 for the nine months ended September 30, 2013 and $7,572,244 for the fiscal year ended December 31, 2012, negative operating cash flows of $163,567 for the nine months ended September 30, 2013 and $1,861,870 for the fiscal year ended December 31, 2012, and incurred additional net losses and negative operating cash flows in the remainder of the 2013 and 2014 fiscal years. The Company expects to continue to incur net losses and negative operating cash flows for several more years thereafter. As a result, management and the Company’s auditors believe that there is substantial doubt about the Company’s ability to continue as a going concern.

	The Company is currently, and has for some time, been in significant financial distress. It has limited cash resources and current assets and has no ongoing source of revenue. Beginning in late 2012, the Company’s business activities were reduced to minimal levels, and the prior Board of Directors of the Company, which was removed by the written consent of stockholders holding a majority of the outstanding shares on March 22, 2013, had retained bankruptcy counsel to assist the Company in preparations to file for liquidation under Chapter 7 of the United States Bankruptcy Code. New management, which was appointed during March and April 2013, has evaluated the status of numerous aspects of the Company’s existing business and obligations, including, without limitation, debt obligations, financial requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has raised new capital to fund its business activities.

	From June 2013 through March 2014, the Company’s Chairman and Chief Executive Officer advanced short-term loans to the Company aggregating $150,000 in order to meet its minimum operating needs. In March and April 2014, the Company completed a private placement by selling 928.5 shares of its Series G Preferred Stock for gross proceeds of $928,500 (see Note 12) and repaid the aggregate advances. The Company’s Chairman and Chief Executive Officer invested $250,000 in the Series G Preferred Stock private placement. On November 5, 2014 and December 9, 2014, the Company sold convertible notes (with warrants) in an aggregate principal amount of $238,500 and $46,000, respectively, to various accredited investors. The purchasers consisted of non-affiliated investors (see Note 12). The Company intends to continue this financing until it has sold an aggregate principal amount of $1,000,000 of such notes, although there can be no assurances that the Company will be successful in this regard.

	The Company will need to raise additional capital, either through the current financing or otherwise, or both, to be able to pay its liabilities and fund its business activities going forward. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies

	Principles of Consolidation

	The accompanying condensed consolidated financial statements include the financial statements of Cortex and Pier, its wholly-owned subsidiary, from its August 10, 2012 acquisition date. Intercompany balances and transactions have been eliminated in consolidation.

	Cash Concentrations

	The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.

	Cash Equivalents

	The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents.

	Concentrations of Credit Risk

	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions.

	Fair Value of Financial Instruments

	The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

	Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

	Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

	Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

	The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

	Deferred and Capitalized Financing Costs

	Costs incurred in connection with ongoing financing activities, including legal and other professional fees, cash finders and placement agent fees, and escrow agent fees, are deferred until the related financing is either completed or abandoned. Costs related to abandoned financings are charged to operations.

	Costs related to completed debt financings are capitalized on the balance sheet and amortized over the term of the related debt agreements. Amortization of these costs is calculated on the straight-line basis, which approximates the effective interest method, and is charged to interest expense in the condensed consolidated statement of operations. Costs related to completed equity financings are charged directly to additional paid-in capital.

	Deferred financing costs, net of accumulated amortization, included in the condensed consolidated balance sheet at September 30, 2013 and December 31, 2012 were $23,301 and $-0-, respectively.

	Furniture and Equipment

	Furniture and equipment are recorded at cost and depreciated on a straight-line basis over the lesser of their estimated useful lives, ranging from three to five years.

	Long-Lived Assets

	The Company reviews its long-lived assets, including intangible assets such as the License Agreement, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually, in conjunction with the preparation of the Company’s fiscal year-end audited financial statements. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company does not have any goodwill.

	License Agreement

	The License Agreement with the University of Illinois acquired in the Pier transaction was an acquired intangible asset recorded at cost of $3,411,157 (based on the fair value ascribed to the License Agreement in August 2012, as described in Note 4), and was being amortized on a straight-line basis over the remaining life of its underlying patents of 172 months from the date of acquisition.

	The Company performed an impairment assessment of the carrying value of the License Agreement as of December 31, 2012 and determined that it had no expected future value at that date. The Company made this determination because it was unable to make a $75,000 payment due under the License Agreement at December 31, 2012, as a result of which the License Agreement was forfeited during the three months ended March 31, 2013. The Company recorded an impairment charge to operations of $3,321,678 at December 31, 2012 to write off the carrying value of the License Agreement (see Note 5).

	Research Grant Revenues

	The Company records research grant revenues when the expenses related to the grant projects are incurred. Amounts received under research grants are nonrefundable, regardless of the success of the underlying research, to the extent that such amounts are expended in accordance with the approved grant project.

	Stock-Based Compensation

	The Company periodically issues common stock and stock options to officers, directors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

	The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.

	Options granted to members of the Company’s Scientific Advisory Board and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.

The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the security as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair value of common stock is determined by reference to the quoted market price of the Company’s common stock.

The Company recognizes the fair value of stock-based compensation in general and administrative costs and in research and development costs, as appropriate, in the Company’s statement of operations.

The Company issues new shares to satisfy stock option exercises.

There were no stock options issued during the nine months ended September 30, 2013. For options granted during the nine months ended September 30, 2012 the fair value of each option award was estimated using the Black-Scholes option-pricing model using the following input variables: expected life – 10 years; expected volatility – 176%; expected dividend yield - 0%; risk-free interest rate – 0.30%.

There were no stock options exercised during the nine months ended September 30, 2013 and 2012.

Income Taxes

The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it projects it will be able to utilize these tax attributes.

As of September 30, 2013, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.

The Company is subject to U.S. federal income tax as well as income tax of multiple state tax jurisdictions. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service for the years ending December 31, 2011 through 2013. The Company and its subsidiary’s state income tax returns (prior to the Pier merger) are open to audit under the statute of limitations for the years ended December 31, 2010 through 2013. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

The Company is currently delinquent with respect to certain of its U.S. federal and applicable states income tax filings and no potential penalties, interest or other charges have been provided for in the Company’s consolidated financial statements because no income was generated during those periods.

Foreign Currency Transactions

The note payable to related party, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related consolidated statement of operations.

Research and Development Costs

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates.

Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.

Comprehensive Income (Loss)

Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the nine months ended September 30, 2013 and 2012.

Earnings per Share

The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.

At September 30, 2013 and 2012, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

		September 30,
		2013		2012
Convertible preferred stock			3,679		3,679
Warrants			5,691,367		22,739,759
Stock options			5,166,668		17,425,024
Total			10,861,714		40,168,462

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts may differ from those estimates.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-08 (ASU 2014-08), Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under ASU 2014-08, only disposals representing a strategic shift in operations or that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. ASU 2014-08 is effective for annual periods beginning after December 15, 2014. As the Company is engaged in research and development activities, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. As the Company does not expect to have any operating revenues for the foreseeable future, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.

In June 2014, the FASB issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminated the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminated an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statement presentation and disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Reclassifications

Certain comparative figures in 2012 have been reclassified to conform to the current year’s presentation. These reclassifications were not material, either individually or in the aggregate.

Merger_with_Pier_Pharmaceutica

Merger with Pier Pharmaceuticals, Inc	9 Months Ended
Merger with Pier Pharmaceuticals, Inc	Sep. 30, 2013
Business Combinations [Abstract]
Merger with Pier Pharmaceuticals, Inc	4. Merger with Pier Pharmaceuticals, Inc.

	On August 10, 2012, pursuant to an Agreement and Plan of Merger by and among Pier, a privately-held corporation, Pier Acquisition Corp., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Cortex, and Cortex, Merger Sub merged with and into Pier and Pier became a wholly-owned subsidiary of Cortex. Pier was formed in June 2007 (under the name SteadySleep Rx Co.) as a clinical stage pharmaceutical company to develop a pharmacologic treatment for the respiratory disorder known as obstructive sleep apnea and had been engaged in research and clinical development activities since formation. As a result, Cortex acquired 100% of the issued and outstanding equity securities of Pier.

	In connection with the merger transaction with Pier, Cortex issued 58,417,893 newly issued shares of its common stock with an aggregate fair value of $3,271,402 ($0.056 per share), based upon the closing price of Cortex’s common stock on August 10, 2012. The shares of common stock were issued to stockholders, convertible note holders, warrant holders, option holders, and certain employees and vendors of Pier in satisfaction of their interests and claims. The common stock issued by Cortex represented approximately 41% of the 144,041,556 common shares outstanding immediately following the closing of the transaction.

	Pier was formed on June 25, 2007 as a closely-held clinical stage pharmaceutical company to develop a pharmacologic treatment for the respiratory disorder known as obstructive sleep apnea and has been engaged in research and early clinical development activities since formation. Pier was a development stage company, as it had not commenced any revenue-generating operations, did not have any cash flows from operations, and was dependent on debt and equity funding to finance its operations.

	On October 10, 2007, Pier obtained the basis for its research and clinical development activities by entering into a License Agreement with the University of Illinois. The License Agreement covered certain patents and patent applications in the United States and other countries claiming the use of certain compounds referred to as cannabinoids, of which dronabinol is a specific example, for the treatment of breathing-related sleep disorders (including sleep apnea). Dronabinol is a synthetic derivative of the naturally occurring substance in the cannabis plant, otherwise known as Δ9-THC (Δ9-tetrahydrocannabinol). Pier’s business plan was to determine whether dronabinol administration to humans would significantly improve subjective and objective clinical measures in patients with obstructive sleep apnea. In addition, Pier intended to evaluate the feasibility and comparative efficacy of a proprietary formulation of dronabinol.

	The License Agreement granted Pier, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the License Agreement, that were then held by the University of Illinois; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the License Agreement, subject to the provisions of the License Agreement. Pier was required under the License Agreement to pay the University of Illinois a license fee, royalties, patent costs and certain milestone payments.

	The License Agreement was the basis for Pier’s research and development activities, and was Pier’s primary asset and its only intellectual property asset. By providing Cortex with the means to expand its respiratory disorders program, the License Agreement was the central reason that Cortex entered into the merger transaction with Pier in August 2012.

	The transaction brought together a series of unique drug products that in preclinical animal models and early clinical studies have shown efficacy in preventing or reversing drug-induced respiratory depression and in reducing obstructive, central and mixed sleep apneas. Phase 2 clinical assets include Cortex’s CX1739, a compound targeting opiate-induced respiratory depression and central sleep apnea, and Pier’s dronabinol, a compound that was, at the time, about to begin a Phase 2B study in obstructive sleep apnea patients that was funded entirely by a National Institutes of Health grant of nearly $5 million. Subsequent to the closing of the transaction, the Company intended to focus entirely on treatments for breathing disorders, and expected to have multiple opportunities for value-generating clinical milestones with dronabinol and CX1739.

	Pursuant to the terms of the transaction, Cortex agreed to issue contingent consideration, consisting of up to approximately 18,300,000 additional shares of common stock, to Pier’s former security holders and certain parties that received the Company’s common stock as part of the Pier transaction if certain of the Company’s stock options and warrants outstanding immediately prior to the closing of the merger were subsequently exercised. In the event that such contingent shares were issued, the ownership percentage of Pier’s former security holders and other parties, following their receipt of such additional shares, could not exceed their ownership percentage as of the initial transaction date.

	The stock options and warrants outstanding at June 30, 2012 were all out-of-the-money on August 10, 2012. During late July and early August 2012, the Company issued options to officers and directors at that time to purchase a total of 7,361,668 shares of common stock exercisable for ten years at $0.06 per share (see Note 9). By October 1, 2012, these options were also out-of-the-money and continued to be out-of-the-money through September 30, 2013. All of the aforementioned options and warrants became increasingly out-of-the-money as December 31, 2012 approached (with most options and warrants being out of the money by multiples of the exercise price at such date), reflecting the fact that the Company’s prospects were very negative. The Company was unable to raise operating capital subsequent to its acquisition of Pier, had run out of working capital and essentially ceased business operations during the fourth quarter of 2012, had not filed its September 30, 2012 Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission due on November 14, 2012, had accepted the resignations of most of its officers and directors, and had prepared to shut-down and liquidate. There were no stock options or warrants exercised subsequent to August 10, 2012, and all of these stock options and warrants were out-of-the-money at September 30, 2013. As of September 30, 2013, approximately 3,200,000 contingent shares of common stock remained issuable under the Pier merger agreement due to forfeitures and expirations of stock options and warrants occurring since August 10, 2012.

	Accordingly, the Company concluded that the issuance of any of the contingent stock consideration was remote, given the large spread between exercise prices of these stock options and warrants as compared to the common stock trading range, the expiration of most of the lower priced option and warrants within two years, the Company’s distressed financial condition and capital requirements, and that these stock options and warrants have remained and have become increasingly out-of-the-money through September 30, 2013, and have continued to expire, as time passes. Accordingly, the Company considered the fair value of the contingent consideration to be immaterial and therefore did not ascribe any value to such contingent consideration; if any such shares are ultimately issued to the former Pier stockholders, the Company will recognize the fair value of such shares as a charge to operations.

	The Company agreed to file a registration statement on Form S-1 under the Securities Act of 1933, as amended, with the SEC within ninety days after the closing of the transaction covering the shares of common stock issued to the former Pier stockholders, as well as the contingent shares, and to take certain other actions to maintain the effectiveness of such registration statement for a period not exceeding three years. The Company has not filed this registration statement. The Agreement and Plan of Merger did not provide for any financial penalties in the event that the Company failed to comply with the registration statement filing requirements.

	The Company accounted for the Pier transaction pursuant to ASC Topic 805, Business Combinations. The Company identified and evaluated the fair value of the assets acquired. Based on the particular facts and circumstances surrounding the history and status of Pier, including its business and intellectual property at the time of the merger transaction, the Company determined that the identifiable intangible assets were comprised solely of a contract-based intangible asset, and that there was no measurable goodwill.

	The intangible asset acquired in the Pier transaction consisted of the License Agreement. Unless terminated earlier, the License Agreement would terminate upon expiration or termination of all patent rights. The License Agreement defined patent rights as all of the University of Illinois’ rights in the patents and patent applications, and (b) all of the University of Illinois’ rights in all divisions, continuations, continuation-in-part applications, reissues, renewals, re-examinations, foreign counterparts, substitutions or extensions thereof. Based upon the expiration date of the underlying patents, the License Agreement would be amortized on a straight-line basis over the remaining life of the underlying patents of 172 months from the date of acquisition.

	The following table summarizes the fair value of the assets acquired and liabilities assumed by the Company at the closing of the Pier transaction on August 10, 2012.

	Fair value of assets acquired:
	Cash	$	23,208
	Other current assets		698
	Equipment		3,463
	License agreement		3,411,157
	Total assets acquired	$	3,438,526

	Consideration transferred by the Company:
	Fair value of common shares issued	$	3,271,402
	Liabilities assumed		167,124
	Total consideration paid	$	3,438,526

	The following pro forma operating data presents the results of operations for the three months and nine months ended September 30, 2012, as if the merger had occurred on the first day of the period presented. The pro forma results are not necessarily indicative of the financial results that might have occurred had the merger transaction actually taken place on the first day of the period presented, or of future results of operations. Pro forma information for the three months and nine months ended September 30, 2012 is summarized as follows:

		Three Months			Nine Months
		Ended			Ended
		30-Sep-12			30-Sep-12
	Total revenues	$	—		$	48,309
	Net loss	$	(731,783	)	$	(2,806,572	)
	Net loss per common share - Basic and diluted	$	(0.01	)	$	(0.02	)
	Weighted average common shares outstanding - Basic and diluted		144,041,556			144,041,556

	As a condition of the Pier transaction, positions for two of Cortex’s executive officers were eliminated and thus the severance agreements for such executive officers were amended. As amended, the severance agreements provided for the grant of fully vested, ten-year options to purchase up to a total of 5,166,668 shares of the Company’s common stock at an exercise price of $0.06 per share, which was in excess of the closing price of the Company’s common stock on the closing date of the Pier acquisition. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model was determined to be $310,000 ($0.06 per share) and was charged to merger costs on August 10, 2012. The Black-Scholes option-pricing model utilized the following inputs: exercise price per share-$0.06; stock price per share – $0.056; expected dividend yield – 0.00%; expected volatility – 176%; average risk-free interest rate – 0.31%; expected life – 10 years. As amended, the severance agreements also required the payment of $429,231 for various other amounts due the two executive officers. As of August 10, 2012, these amounts were accrued and charged to merger costs. As a result of the management change that occurred on March 22, 2013, these officers asserted claims against the Company (see Note 12).

	Pier merger-related costs for the year ended December 31, 2012 are summarized as follows:

	Direct merger costs	$	506,876
	Merger-related severance and termination costs		739,231
	Total	$	1,246,107

	The License Agreement was terminated effective March 21, 2013 due to the Company’s failure to make a required payment (see Note 5). New management subsequently opened negotiations with the University of Illinois, as a result of which the Company ultimately entered into a new license agreement with the University of Illinois on June 27, 2014, the material terms of which were similar to the License Agreement that had been terminated on March 21, 2013 (see Note 12).

Impairment_and_Termination_of_

Impairment and Termination of University of Illinois License Agreement	9 Months Ended
	Sep. 30, 2013
Impairment And Termination Of University Of Illinois License Agreement
Impairment and Termination of University of Illinois License Agreement	5. Impairment and Termination of University of Illinois License Agreement

	At December 31, 2012, the Company was obligated to pay a $75,000 milestone fee to the University of Illinois under the License Agreement (see Note 4). At such date, due to the Company’s distressed financial condition, lack of working capital and inability to raise additional operating capital, the Company was unable to make such payment on a timely basis, or within the 30-day cure period.

	At December 31, 2012, the Company determined that the License Agreement would be forfeited during the first quarter of the 2013 fiscal year. Accordingly, the License Agreement had no expected future value and was therefore impaired at December 31, 2012, as a result of which the Company recorded a charge to operations of $3,321,678 at December 31, 2012 (reflecting the remaining unamortized carrying value of the License Agreement at December 31, 2012).

	Subsequently, on February 19, 2013, the University of Illinois notified the Company that it had defaulted under the License Agreement due to non-payment of the $75,000 milestone fee due December 31, 2012. On March 22, 2013, the University of Illinois notified the Company that the License Agreement had been terminated effective March 21, 2013 due to the Company’s failure to make the required $75,000 payment.

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable

	Note Payable to Related Party

	On June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to approximately $400,000 US dollars) from and executed a secured note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“Samyang”), an approximately 20% common stockholder of the Company at that time. The note accrues simple interest at the rate of 12% per annum and has a maturity date of June 25, 2013, although Samyang was permitted to demand early repayment of the promissory note on or after December 25, 2012. Samyang did not demand early repayment. The Company has not made any payments on the promissory note. At June 30, 2013 and subsequently, the promissory note was outstanding and in technical default, although Samyang had not issued a notice of default or a demand for repayment. The Company believes that Samyang is in default of its obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a notice of default. The Company anticipates entering into discussions with Samyang with a view toward a comprehensive resolution of the aforementioned matters.

	Pursuant to the terms of this borrowing arrangement, Samyang was granted the right to designate a representative to serve on the Company’s Board of Directors, pursuant to which Samyang designated Moogak Hwang, Ph.D. as its representative. In this regard, the Company elected Dr. Hwang to its Board of Directors on August 3, 2012. Dr. Hwang resigned from the Company’s Board of Directors effective September 30, 2013.

	The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds. The security interest does not extend to the Company’s patents for its ampakine compounds CX1739 and CX1942, or to the patent for the use of ampakine compounds for the treatment of respiratory depression.

	In connection with this financing, the Company issued to Samyang two-year detachable warrants to purchase 4,000,000 shares of the Company’s common stock at a fixed exercise price of $0.056 per share. The warrants have a call right for consideration of $0.001 per share, in favor of the Company, to the extent that the weighted average closing price of the Company’s common stock exceeds $0.084 per share for each of ten consecutive trading days, subject to certain circumstances. Additionally, an existing license agreement with Samyang was expanded to include rights to ampakine CX1739 in South Korea for the treatment of sleep apnea and respiratory depression. The unexercised warrants expired on June 25, 2014.

	The Company used the Black-Scholes option-pricing model to estimate the fair value of the two-year detachable warrants to purchase 4,000,000 shares of the Company’s common stock at a fixed exercise price of $0.056 per share. The Company applied the relative fair value method to allocate the proceeds from the borrowing to the note payable and the detachable warrants. The Company did not consider the expansion of the existing license agreement with Samyang to have any significant value. Consequently, approximately 64% of the proceeds of the borrowing were attributed to the debt instrument.

	The 36% value attributed to the warrant was amortized as additional interest expense over the life of the note. Additionally, financing costs aggregating $21,370 incurred in connection with the transaction were also amortized over the expected life of the note. In that repayment could be demanded after six months, that period was used as the expected life of the note payable for amortization purposes.

	Note payable to Samyang consists of the following at September 30, 2013 and December 31, 2012:

		30-Sep-13		31-Dec-12
	Principal amount of note payable	$	399,774	$	399,774
	Accrued interest payable		61,719		25,340
	Foreign currency transaction adjustment		36,784		40,278
		$	498,277	$	465,392

	Notes Payable to Chairman

	On June 25, 2013, the Arnold Lippa Family Trust, an affiliate of Dr. Lippa, the Company’s Chairman and Chief Executive Officer, began advancing funds to the Company in order to meet minimum operating needs. At September 30, 2013, Dr. Lippa had advanced $40,000 to the Company. Such advances reached a maximum of $150,000 on March 3, 2014 and were due on demand with interest at a rate per annum equal to the “Blended Annual Rate”, as published by the U.S. Internal Revenue Service, of approximately 0.22% for the period outstanding. In March 2014, the Company repaid the working capital advances, including accrued interest of $102, with the proceeds from the private placement of its Series G Preferred Stock (see Note 12).

Furniture_Equipment_and_Leasho

Furniture, Equipment and Leashold Improvements	9 Months Ended
Furniture, Equipment and Leashold Improvements	Sep. 30, 2013
Property, Plant and Equipment [Abstract]
Furniture, Equipment and Leasehold Improvements	7. Furniture, Equipment and Leasehold Improvements

	During the year ended December 31, 2012, in connection with the downsizing of the Company’s operations, the Company disposed of furniture, equipment and leasehold improvements costing a total of $1,170,849. Of that amount, $898,731 occurred during the nine months ended September 30, 2012.

	On May 14, 2012, the Company executed a three-year lease for office space beginning June 1, 2012 at a monthly rate of $9,204. During the three months ended December 31, 2012, the Company substantially vacated its operating facility and abandoned its furniture, equipment and leasehold improvements. In May 2013, the Company received notice that it had been sued in the Superior Court of California in a complaint filed on March 28, 2013 by its former landlord, PPC Irvine Center Investment, LLC, seeking among other things, $57,535 in past due rent, termination of the lease agreement, and reasonable attorney’s fees. On May 23, 2013, a settlement was reached with the landlord that provided for the Company to relinquish its security deposit in the amount of $29,545, transfer title to its remaining furniture, equipment and leasehold improvements, and pay an additional $26,000. The transfer of the Company’s furniture, equipment and leasehold improvements resulted in a loss of $39,126, which was recorded at December 31, 2012. During the nine months ended September 30, 2013, the Company recorded a gain of $1,990 with respect to the final disposition of this matter.

	In order to estimate the fair value of the liability to be accrued with respect to the Company’s potential liability under the abandoned lease at December 31, 2012, the Company considered various factors, including the current lease rates for similar office space in Irvine, California, the desirability of the area to businesses, and the estimated time that it would take to find a new tenant for the office space. Taking these factors into account, the Company concluded that the potential rental income from a sublease of its operating facility would equal or exceed the Company’s remaining lease obligation. The Company also considered the negotiations with the landlord during May 2013, which indicated that a settlement for substantially less than the remaining payments under the lease was more likely than not to be successful.

Project_Advance

Project Advance	9 Months Ended
Project Advance	Sep. 30, 2013
Project Advance
Project Advance	8. Project Advance

	In June 2000, the Company received $247,300 from the Institute for the Study of Aging (the “Institute”) to fund testing of CX516, the Company’s ampakine in patients with mild cognitive impairment (“MCI”). Patients with MCI represent the earliest clinically-defined group with memory impairment beyond that expected for normal individuals of the same age and education, but such patients do not meet the clinical criteria for Alzheimer’s disease. During 2002 and 2003, the Company conducted a double-blind, placebo-controlled clinical study with 175 elderly patients displaying MCI and issued a final report on June 21, 2004. CX516 did not improve the memory impairments observed in these patients.

	Pursuant to the funding agreement, if the Company complied with certain conditions, including the completion of the MCI clinical trial, the Company would not be required to make any repayments unless and until the Company enters one of its ampakine compounds into a Phase 3 clinical trials for Alzheimer’s disease. Upon initiation of such clinical trials, repayment would include the principal amount plus accrued interest computed at a rate equal to one-half of the prime lending rate. In the event of repayment, the Institute could elect to receive the outstanding principal balance and any accrued interest thereon in shares of the Company’s common stock. The conversion price for such form of repayment was fixed at $4.50 per share and was subject to adjustment if the Company paid a dividend or distribution in shares of common stock, effected a stock split or reverse stock split, effected a reorganization or reclassification of its capital stock, or effected a consolidation or merger with or into another corporation or entity. Included in the condensed consolidated balance sheets is principal and accrued interest with respect to this funding agreement in the amount of $333,069 and $330,022 at September 30, 2013 and December 31, 2012, respectively.

	The Company entered into an agreement with the Institute on September 2, 2014 to settle this obligation by issuing 1,000,000 shares of the Company’s restricted common stock (see Note 12). The note payable, including accrued interest, had an approximate balance of $337,000 on such date.

Stockholders_Equity

Stockholders' Equity

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

Stockholders' Equity

9. Stockholders’ Equity

Preferred Stock

The Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of September 30, 2013 and December 31, 2012, 1,250,000 shares were designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred”); 37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred”); 205,000 were designated as Series A Junior Participating Preferred Stock (non-voting, “Series A Junior Participating”) and 3,507,500 shares were undesignated and may be issued with such rights and powers as the Board of Directors may designate.

None of the 9% Preferred shares or the Series A Junior Participating shares were outstanding as of September 30, 2013 or December 31, 2012.

Series B Preferred shares outstanding as of September 30, 2013 and December 31, 2012 consisted of 37,500 shares issued in a May 1991 private placement. Each share of Series B Preferred is convertible into approximately 0.09812 shares of common stock at an effective conversion price of $6.795 per share of common stock, which is subject to adjustment under certain circumstances. As of September 30, 2013 and December 31, 2012, these shares of Series B Preferred outstanding are convertible into 3,679 shares of common stock. The Company may redeem the Series B Preferred for $25,001, equivalent to $0.6667 per share, an amount equal to its liquidation preference, at any time upon 30 days prior notice.

On March 14, 2014, the Company designated 1,700 shares of the previously undesignated shares of preferred stock as Series G Preferred Stock (see Note 12).

Common Stock and Common Stock Purchase Warrants

Under the terms of the Company’s registered direct offering with several institutional investors in January 2007, the Company sold an aggregate of 5,021,427 shares of its common stock and warrants to purchase 3,263,927 shares of its common stock. The warrants had an exercise price of $1.66 per share and were exercisable on or before January 21, 2012. During the year ended December 31, 2007, the Company received approximately $443,000 from the partial exercise of such warrants. None of the remaining warrants to purchase 2,996,927 shares of the Company’s common stock were exercised, and consequently, those unexercised warrants expired in January 2012.

Under the terms of the Company’s registered direct offering with several institutional investors in August 2007, the Company sold an aggregate of 7,075,000 shares of its common stock and warrants to purchase 2,830,000 shares of its common stock. The warrants had an exercise price of $2.64 per share and were exercisable on or before August 28, 2012. In addition, the Company issued warrants to purchase an aggregate of 176,875 shares of its common stock to the placement agents in that offering. The placement agent warrants had an exercise price of $3.96 per share and were also exercisable on or before August 28, 2012. None of those investor or placement agent warrants were exercised, and consequently, those unexercised warrants to purchase 3,006,875 shares of the Company’s common stock expired in August 2012.

In connection with the registered direct offering of the Company’s 0% Series E Convertible Preferred Stock in April 2009, the Company issued warrants to purchase an aggregate of 6,941,176 shares of its common stock to a single institutional investor. The warrants had an exercise price of $0.3401 per share and were exercisable on or before October 17, 2012. In February 2010, the exercise price of these warrants was reduced to $0.2721 in exchange for the investor’s consent and waiver with respect to the Company’s completed financing transaction with Samyang in January 2010. The warrants were also subject to a call provision in favor of the Company. The Company also issued warrants to purchase an additional 433,824 shares of the Company’s common stock to the placement agent for that transaction. These warrants had an exercise price of $0.26 per share and were subject to the same exercisability term as the warrants issued to the investor. None of those investor or placement agent warrants were exercised, and consequently, those unexercised warrants to purchase 7,375,000 shares of the Company’s common stock expired in August 2012.

In connection with the private placement of the Company’s Series F Convertible Preferred Stock in July 2009, the Company issued warrants to purchase an aggregate of 6,060,470 shares of its common stock to a single institutional investor. The warrants had an exercise price of $0.2699 per share and were exercisable on or before January 31, 2013. The Company also issued warrants to purchase an additional 606,047 shares of the Company’s common stock to the placement agent for that transaction. These warrants had an exercise price of $0.3656 per share and were subject to the same exercisability term as the warrants issued to the investor. The warrants issued to the investor and the placement agent were subject to a call provision in favor of the Company. None of those investor or placement agent warrants were exercised, and consequently, those unexercised warrants to purchase 6,666,517 shares of the Company’s common stock expired in January 2013.

In connection with the conversion of a promissory note issued to Samyang in June 2010, the Company issued to Samyang two-year warrants to purchase 4,081,633 shares of the Company’s common stock at an exercise price of $0.206 per share. None of those warrants were exercised, and consequently, those unexercised warrants to purchase 4,081,633 shares of the Company’s common stock expired in June 2012.

In October 2011, the Company completed a private placement of $500,000 in securities with Samyang Value Partners Co., Ltd., a wholly-owned subsidiary of Samyang. The transaction included the issuance of 6,765,466 shares of the Company’s common stock and two-year warrants to purchase an additional 1,691,367 shares of its common stock. The warrants had an exercise price of $0.1035 per share and a call right in favor of the Company. None of those warrants were exercised, and consequently, those unexercised warrants to purchase 1,691,367 shares of the Company’s common stock expired in October 2013. Related to this private placement, the Company and Samyang entered into a non-binding memorandum of understanding (“MOU”) regarding a potential license agreement for rights to the ampakine CX1739 for the treatment of neurodegenerative diseases in South Korea. The MOU also provided Samyang with rights of negotiation to expand its territory into other South East Asian countries, excluding Japan, Taiwan and China, and to include rights to the high impact ampakine CX1846 for the potential treatment of neurodegenerative diseases. The related license agreement was subsequently completed in January 2012.

In connection with a private placement of debt on June 25, 2012, the Company issued to Samyang two-year detachable warrants to purchase 4,000,000 shares of the Company’s common stock at a fixed exercise price of $0.056 per share (see Note 6). The warrants had a call right for consideration of $0.001 per share, in favor of the Company, to the extent that the weighted average closing price of the Company’s common stock exceeded $0.084 per share for each of ten consecutive trading days, subject to certain circumstances. The warrants expired unexercised in June 2014.

A summary of warrant activity for the nine months ended September 30, 2013 is presented below.

Number of

Weighted

Average

Exercise Price

Remaining

Contractual

Life (in Years)

Warrants outstanding at December 31, 2012

12,357,884

0.182

Issued

—

Exercised

—

Expired

(6,666,517

)

0.279

Warrants outstanding at September 30, 2013

5,691,367

0.069

0.53

Warrants exercisable at December 31, 2012

12,357,884

0.182

Warrants exercisable at September 30, 2013

5,691,367

0.069

0.53

The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2013:

Exercise Price

Warrants

Expiration Date

Outstanding

Exercisable

(Shares)

0.056

4,000,000

25-Jun-14

0.1

1,691,367

October 20, 2013

5,691,367

Based on a fair market value of $0.04 per share on September 30, 2013, there were no exercisable in-the-money stock warrants as of September 30, 2013.

Stock Option and Stock Purchase Plan

The Company’s 1996 Stock Incentive Plan (the “1996 Plan”), which terminated pursuant to its terms on October 25, 2006, provided for the granting of options and rights to purchase up to an aggregate of 10,213,474 shares of the Company’s authorized but unissued common stock to qualified employees, officers, directors, consultants and other service providers. Options granted under the 1996 Plan generally vested over a three-year period, although some options granted to officers included more accelerated vesting. Options previously granted under the 1996 Plan generally expire ten years from the date of grant, but some options granted to consultants expire five years from the date of grant. Pursuant to the 1996 Plan, options are generally forfeited three months from the date of termination of an optionee’s continuous service if such termination occurs for any reason other than permanent disability or death.

On March 30, 2006, the Company’s Board of Directors approved the 2006 Stock Incentive Plan (the “2006 Plan”), which subsequently was approved by the Company’s stockholders on May 10, 2006. Upon the approval of the 2006 Plan, no further options were granted under the 1996 Plan. The 2006 Plan provides for the granting of options and rights to purchase up to an aggregate of 9,863,799 shares of the Company’s authorized but unissued common stock (subject to adjustment under certain circumstances, such as stock splits, recapitalizations and reorganization) to qualified employees, officers, directors, consultants and other service providers.

Under the 2006 Plan, the Company may issue a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options, nonqualified stock options, restricted stock grants, stock appreciation rights, stock payment awards, restricted stock units and dividend equivalents. The exercise price of stock options offered under the 2006 Plan must be at least 100% of the fair market value of the common stock on the date of grant. If the person to whom an incentive stock option is granted is a 10% stockholder of the Company on the date of grant, the exercise price per share shall not be less than 110% of the fair market value on the date of grant. Vesting and expiration provisions for options granted under the 2006 Plan are similar to those under the 1996 Plan. Pursuant to the 2006 Plan, options are generally forfeited ninety days from the date of termination of an optionee’s continuous service if such termination occurs for any reason other than permanent disability or death.

Subject to any restrictions under federal or securities laws, the Chief Executive Officer may award stock options to new non-executive officer employees and consultants, with a market value at the time of hire equivalent to up to 100% of the employee’s annual salary or the consultant’s anticipated annual consulting fees. The Chief Executive Officer shall have the discretion to increase or decrease such awards based on market and recruiting factors subject to a limit per person in each case of options to purchase 50,000 shares. Additionally, on an annual basis, the Chief Executive Officer may grant continuing employees and consultants, based upon performance and subject to meeting objectives, a stock option for that number of shares up to 40% of the employee’s annual salary or the consultant’s annual fees, but not to exceed 50,000 shares per person per year. Any option grant exceeding 50,000 shares per person per year requires approval by the Compensation Committee of the Board of Directors or the full Board of Directors. These options shall be granted with an exercise price equal to the fair market value of the Company’s common stock on the date of issuance, have a ten-year term, vest annually over a three-year period from the dates of grant and have other terms consistent with the 2006 Plan.

Under the 2006 Plan, each non-employee director is automatically granted options to purchase 30,000 shares of common stock upon commencement of service as a director and, each non-employee director is automatically granted additional options to purchase 30,000 shares of common stock on the date of the first meeting of the Board of Directors for the relative calendar year. The nonqualified options to non-employee directors have an exercise price equal to 100% of the fair market value of the common stock on the date of grant, have a ten-year term and vest annually over a three-year period from the dates of grant.

On August 3, 2012, fully vested, ten-year options to purchase a total of 2,195,000 shares of the Company’s common stock at an exercise price of $0.06 per share, representing the closing price of the Company’s common stock on the date of issue, were granted to directors of the Company for past services. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $131,700 ($0.06 per share), which was charged to general and administrative expense on that date.

In July and August 2012, pursuant to severance agreements amended in connection with the merger transaction with Pier, fully-vested, ten-year options to purchase a total of 5,166,668 shares of the Company’s common stock at an exercise price of $0.06 per share, which was in excess of the closing price of the Company’s common stock on the closing date of the merger, were granted to two of the Company’s former executive officers. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $310,000 ($0.06 per share), which was charged to merger-related costs on the dates of grant.

The Company is no longer making awards under the 2006 Plan and has adopted, with stockholder approval, the 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (see Note 11).

As of September 30, 2013, options to purchase an aggregate of 5,166,668 shares of common stock were exercisable under the Company’s stock option plans. During the nine months ended September 30, 2013, the Company did not issue any options to purchase shares of common stock.

A summary of stock option activity for the six months ended September 30, 2013 is presented below.

Number

Weighted

Average

Exercise

Remaining Contractual

Price

Life

(in Years)

Options outstanding at December 31, 2012

10,754,155

0.557

Granted

—

Expired

—

Forfeited

(5,587,487

)

1.018

Options outstanding at September 30, 2013

5,166,668

0.06

8.87

Options exercisable at December 31, 2012

10,754,155

0.557

Options exercisable at September 30, 2013

5,166,668

0.06

8.87

As all stock options outstanding were fully vested at September 30, 2013, there is no compensation expense to be recognized in future periods with respect to such options.

The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2013:

Exercise

Options

Expiration

Price

Outstanding

Exercisable

Date

(Shares)

0.06

3,083,334

17-Jul-22

0.06

2,083,334

August 10, 2022

5,166,668

Based on a fair market value of $0.04 per share on September 30, 2013, there were no exercisable in-the-money stock options as of September 30, 2013.

As of September 30, 2013, the Company had reserved an aggregate of 3,679 shares for issuance upon conversion of the Series B Preferred; 5,691,367 shares for issuance upon exercise of warrants; 5,166,668 shares for issuance upon exercise of outstanding stock options; and 9,863,799 shares for issuance upon exercise of stock options available for future grant pursuant to the 2006 Plan. The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

For the three months ended September 30, 2013 and 2012, stock-based compensation costs included in the statements of operations consisted of general and administrative expenses of $-0- and $142,975, respectively, and research and development expenses of $-0- and $1,702, respectively. For the nine months ended September 30, 2013 and 2012, stock-based compensation costs included in the statements of operations consisted of general and administrative expenses of $-0- and $170,805, respectively, and research and development expenses of $-0- and $8,513, respectively.

As of September 30, 2013, the Company had reserved an aggregate of 3,679 shares for issuance upon conversion of the Series B Preferred; 5,691,367 shares for issuance upon exercise of warrants; 5,166,668 shares for issuance upon exercise of outstanding stock options; 9,863,799 shares for issuance upon exercise of stock options available for future grant pursuant to the 2006 Plan; and 3,239,023 shares issuable as contingent shares pursuant to the Pier merger (see Note 4). The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

Stockholder Rights Plan

On February 5, 2002, the Company’s Board of Directors approved the adoption of a Stockholder Rights Plan to protect stockholder interests against takeover strategies that may not provide maximum stockholder value. A dividend of one Right (each, a “Right” and, collectively, the “Rights”) for each outstanding share of the Company’s common stock was distributed to stockholders of record on February 15, 2002. The Stockholder Rights Plan terminated and the related Rights expired by their terms on February 15, 2012.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2013
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions

	In 2012, Aurora Capital LLC provided investment banking services to Pier, a company that the Company acquired by merger on August 10, 2012 (see Note 4). For those services, on August 10, 2012 Aurora Capital LLC received 2,971,792 shares of the Company’s common stock in payment of its fee of $194,950. Both Arnold Lippa and Jeff Margolis, officers and directors of the Company since March 22, 2013, have indirect ownership interests in Aurora Capital LLC through interests held in its members.

	On March 31, 2013, the Company accrued $85,000 as reimbursement for legal fees incurred by Aurora Capital LLC in conjunction with the removal of the Company’s prior Board of Directors on March 22, 2013 (see Note 2).

	See Notes 6 and 9 for a description of transactions with Samyang, a significant stockholder of the Company and a lender to the Company.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies

	Pending or Threatened Legal Actions and Claims

	The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s financial statements with respect to such matters.

	The Company’s former Vice President and Chief Financial Officer has asserted certain claims for compensation against the Company through the date of her resignation from the Company on October 26, 2012. The Company is engaged in negotiations with this former officer to resolve this matter in its entirety to avoid litigation, but there can be no assurances that the Company will be successful in such endeavor. To the extent that the former officer files a formal complaint or other legal claim against the Company, the Company intends to defend itself through the appropriate legal process and will consider all available options, including filing legal counter-claims. In the opinion of management, the Company has made adequate provision for any liability relating to this matter in its financial statements at September 30, 2013.

	A former director of the Company, who joined the Company’s Board of Directors on August 10, 2012 in conjunction with the Pier transaction and who resigned from the Company’s Board of Directors on September 28, 2012, has asserted certain claims for consulting compensation against the Company. In the opinion of management, the Company has made adequate provision for any liability relating to this matter in its financial statements at September 30, 2013.

	Lease Commitment

	On May 14, 2012, the Company executed a three-year lease for office space beginning June 1, 2012 at a monthly rate of $9,204. During the three months ended December 31, 2012, the Company substantially vacated its operating facility prior to the scheduled termination of the lease agreement in May 2015. In May 2013, a settlement with the landlord was reached and the lease was terminated (see Note 7).

	University of California, Irvine License Agreements

	The Company entered into a series of license agreements in 1993 and 1998 with UCI that granted the Company proprietary rights to certain chemical compounds that acted as ampakines and their therapeutic uses. These agreements granted the Company, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the license agreement, that were then held by UCI; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the license agreements, subject to the provisions of the license agreements. The Company was required, among other terms and conditions, to pay UCI a license fee, royalties, patent costs and certain additional payments.

	Under such license agreements, the Company was required to make minimum annual royalty payments of approximately $70,000. The Company was also required to spend a minimum of $250,000 per year to advance the ampakine compounds until the Company began to market an ampakine compound. The commercialization provisions in the agreements with UCI required the Company to file for regulatory approval of an ampakine compound before October 2012. In March 2011, UCI agreed to extend the required date for filing regulatory approval of an ampakine compound to October 2015. At December 31, 2012, the Company was not in compliance with its minimum annual payment obligations and believed that this default constituted a termination of the license agreements.

	On April 15, 2013, the Company received a letter from UCI indicating that the license agreements between UCI and the Company had been terminated due to the Company’s failure to make certain payments required to maintain the agreements. Since the patents covered in these license agreements had begun to expire and the therapeutic uses described in these patents were no longer germane to the Company’s new focus on respiratory disorders, the loss of these license agreements is not expected to have a material impact on the Company’s current drug development programs. In the opinion of management, the Company has made adequate provision for any liability relating to this matter in its condensed consolidated financial statements at September 30, 2013.

	University of Alberta License Agreement

	On May 8, 2007, the Company entered into a license agreement, as amended, with the University of Alberta granting the Company exclusive rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. The Company agreed to pay the University of Alberta a licensing fee and a patent issuance fee, which were paid, and prospective payments consisting of a royalty on net sales, sublicense fee payments, maintenance payments and milestone payments. The prospective maintenance payments commence on the enrollment of the first patient into the first Phase 2B clinical trial and increase upon the successful completion of the Phase 2B clinical trial. As the Company does not at this time anticipate scheduling a Phase 2B clinical trial, no maintenance payments are currently due and payable to the University of Alberta. In addition, no other prospective payments are currently due and payable to the University of Alberta.

Subsequent_Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2013
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events

	Series G Preferred Stock Placement

	On March 14, 2014, the Company filed a Certificate of Designation, Preferences, Rights and Limitations, (the “Certificate of Designation”) of its Series G Preferred Stock (“Series G Preferred Stock”) with the Secretary of State of the State of Delaware to amend the Company’s certificate of incorporation. The number of shares designated as Series G Preferred Stock is 1,700 (which shall not be subject to increase without the written consent of a majority of the holders of the Series G Preferred Stock or as otherwise set forth in the Certificate of Designation). The Stated Value of each share of Series G Preferred Stock is $1,000.

	The Company shall pay a stated dividend on the Series G Preferred Stock at a rate per share (as a percentage of the Stated Value per share) of 1.5% per annum, payable quarterly within 15 calendar days of the end of each fiscal quarter of the Company, in duly authorized, validly issued, fully paid and non-assessable shares of Series G Preferred Stock, which may include fractional shares of Series G Preferred Stock.

	The Series G Preferred Stock shall be convertible, beginning 60 days after the last share of Series G Preferred Stock is issued in the Private Placement, at the option of the holder, into common stock at the applicable conversion price, at a rate determined by dividing the Stated Value of the shares of Series G Preferred Stock to be converted by the conversion price, subject to adjustments for stock dividends, splits, combinations and similar events as described in the form of Certificate of Designation. The stated value of the Series G Preferred Stock is $1,000 per share, and the fixed conversion price is $0.0033. Accordingly, at the option of the holder, each share of Series G Preferred Stock is convertible commencing on the date that is 60 calendar days after the date on which the last share of Series G Preferred Stock is issued pursuant to a Purchase Agreement, into 303,030 shares of common stock. In addition, the Company has the right to require the holders of the Series G Preferred Stock to convert such shares into common stock under certain enumerated circumstances as set forth in the Certificate of Designation.

	Upon either (i) a Qualified Public Offering (as defined in the Certificate of Designation) or (ii) the affirmative vote of the holders of a majority of the Stated Value of the Series G Preferred Stock issued and outstanding, all outstanding shares of Series G Preferred Stock, plus all accrued or declared, but unpaid, dividends thereon, shall mandatorily be converted into such number of shares of common stock determined by dividing the Stated Value of such Series G Preferred Stock (together with the amount of any accrued or declared, but unpaid, dividends thereon) by the Conversion Price (as defined in the Certificate of Designation). If not earlier converted, the Series G Preferred Stock shall be redeemed by conversion on the two year anniversary of the date the last share of Series G Preferred Stock is issued in the Private Placement at the Conversion Price.

	Except as described in the Certificate of Designation, holders of the Series G Preferred Stock will vote together with holders of the Company common stock on all matters, on an as-converted to common stock basis, and not as a separate class or series (subject to limited exceptions).

	In the event of any liquidation or winding up of the Company prior to and in preference to any Junior Securities (including common stock), the holders of the Series G Preferred Stock will be entitled to receive in preference to the holders of the Company common stock a per share amount equal to the Stated Value, plus any accrued and unpaid dividends thereon.

	On March 18, 2014, the Company entered into Securities Purchase Agreements with various accredited investors (the “Initial Purchasers”), pursuant to which the Company sold an aggregate of 753.22 shares of its Series G Preferred Stock for a purchase price of $1,000 per share, or an aggregate purchase price of $753,220. This financing represents the initial closing on a private placement of up to $1,500,000 (the “Private Placement”). The Initial Purchasers in this tranche of the Private Placement consisted of (i) Arnold S. Lippa, the Company’s Chairman, Chief Executive Officer and a member of the Company’s Board of Directors, who invested $250,000 for 250 shares of Series G Preferred Stock, and (ii) new, non-affiliated, accredited investors. Neither the Series G Preferred Stock nor the underlying shares of common stock have any registration rights.

	The placement agents and selected dealers in connection with the initial tranche of the Private Placement received cash fees totaling $3,955 as compensation and warrants totaling approximately 5.6365% of the shares of common stock into which the Series G Preferred Stock may convert, exercisable for five years at a fixed price of $0.00396, which is 120% of the conversion price at which the Series G Preferred Stock may convert into the Company’s common stock. Aurora Capital LLC was one of the placement agents.

	On April 17, 2014, the Company entered into Securities Purchase Agreements with various accredited investors (together with the Initial Purchasers, the “Purchasers”), pursuant to which the Company sold an aggregate of 175.28 shares of its Series G Preferred Stock, for a purchase price of $1,000 per share, or an aggregate purchase price of $175,280. This was the second and final closing on the Private Placement. The Purchasers in the second and final tranche of the Private Placement consisted of new, non-affiliated, accredited investors and non-management investors who had also invested in the first closing. One of the investors in this second and final closing was an affiliate of an associated person of Aurora Capital LLC. Neither the Series G Preferred Stock nor the underlying shares of common stock have any registration rights.

	The placement agents and selected dealers in connection with the second tranche of the Private Placement received cash fees of $3,465 as compensation and warrants totaling approximately 12% of the shares of common stock into which the Series G Preferred Stock may convert, exercisable for five years at a fixed price of $0.00396, which is 120% of the conversion price at which the Series G Preferred Stock may convert into the Company’s common stock. Aurora Capital LLC was one of the placement agents.

	The stated value of the Series G Preferred Stock is $1,000 per share, and the fixed conversion price is $0.0033. Accordingly, at the option of the holder, each share of Series G Preferred Stock is convertible commencing on the date that is sixty calendar days after the date on which the last share of Series G Preferred Stock is issued pursuant to a Purchase Agreement, into 303,030 shares of common stock. The aggregate of 928.5 shares of Series G Preferred Stock sold in the Private Placement are convertible into a total of 281,363,634 shares of common stock. The Company had 144,041,556 shares of common stock, plus an additional 57,000,000 shares of common stock issued to management on April 14, 2014, issued and outstanding immediately prior to the closing of the Private Placement of Series G Preferred Stock described herein.

	The warrants that the placement agents and selected dealers received in connection with the Private Placement represent the right to acquire 19,251,271 shares of common stock exercisable for five years at a fixed price of $0.00396, which is 120% of the conversion price at which the Series G Preferred Stock may convert into the Company’s common stock.

	Purchasers in the Private Placement of the Series G Preferred Stock have executed written consents in favor of (i) approving and adopting an amendment to the Company’s certificate of incorporation that increases the number of authorized shares of the Company to 1,405,000,000, 1,400,000,000 of which are shares of common stock and 5,000,000 of which are shares of preferred stock, and (ii) approving and adopting the Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan.

	The shares of Series G Preferred Stock were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. The shares of Series G Preferred Stock and the Company’s common stock issuable upon conversion of the shares of Series G Preferred Stock have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

	Convertible Note and Warrant Financing

	On November 5, 2014, the Company entered into a Convertible Note and Warrant Purchase Agreement (the “Purchase Agreement”) with various accredited, non-affiliated investors (each, a “Purchaser”), pursuant to which the Company sold an aggregate principal amount of $238,500 of its (i) 10% Convertible Notes due September 15, 2015 (each a “Note”, and together, the “Notes”) and (ii) Warrants to purchase shares of common stock (the “Warrants”). This financing represents the initial closing on a private placement of up to $1,000,000, and the Company may close on one or more additional tranches of this private placement in the near future. Unless otherwise provided for in the Notes, the outstanding principal balance of each Note and all accrued and unpaid interest is due and payable in full on September 15, 2015. At any time, each Purchaser may elect, at its option and in its sole discretion, to convert the outstanding principal amount into a fixed number of shares of the Company’s common stock equal to the quotient obtained by dividing the outstanding principal amount by $0.035 (an aggregate of 6,814,286 shares), plus any accrued and unpaid interest, which is treated in the same manner as the outstanding principal amount. In the case of a Qualified Financing (as defined in the Purchase Agreement), the outstanding principal amount and accrued and unpaid interest under the Notes automatically convert into common stock at a common stock equivalent price of $0.035. In the case of an Acquisition (as defined in the Purchase Agreement), the Company may elect to either: (i) convert the outstanding principal amount and all accrued and unpaid interest under the Notes into shares of common stock or (ii) accelerate the maturity date of the Notes to the date of closing of the Acquisition. Each Warrant to purchase shares of common stock shall be exercisable into a fixed number of shares of common stock of the Company calculated as each Purchaser’s investment amount divided by $0.035 (an aggregate of 6,814,286 shares). The Warrants do not have any cashless exercise provisions and are exercisable through September 15, 2015 at a fixed price of $0.035 per share.

	On December 9, 2014, a second closing for $46,000 was conducted under this financing.

	Placement agent fees, brokerage commissions, finder’s fees and similar payments were made in the form of cash and warrants to qualified referral sources in connection with the sale of the Notes and Warrants. In connection with the initial closing, fees of $16,695 were paid in cash, based on 7% of the aggregate principal amount of the Notes issued to such referral sources, and the fees paid in warrants (the “Placement Agent Warrants”) consisted of 477,000 warrants, reflecting warrants for that number of shares equal to 7% of the number of shares of common stock into which the corresponding Notes are convertible. In connection with the second closing, fees of $700 were paid in cash and 20,000 Placement Agent Warrants were issued. The Placement Agent Warrants have cashless exercise provisions and are exercisable through September 15, 2015 at a fixed price of $0.035 per share. Aurora Capital LLC is acting as the placement agent for this financing.

	The Notes and Warrants were offered and sold without registration under the Securities Act in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The Notes and Warrants and the shares of common stock issuable upon conversion of the Notes and exercise of the Warrants have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

	Exercise of Placement Agent and Selected Dealer Warrants

	Effective August 25, 2014, a warrant issued on April 17, 2014 in conjunction with the Private Placement of the Series G Preferred Stock, representing the right to acquire a total of 2,112,879 shares of common stock, was exercised in full on a cashless basis, resulting in the net issuance of 1,942,124 shares of common stock.

	Effective September 5, 2014, a warrant issued on April 17, 2014 in conjunction with the Private Placement of the Series G Preferred Stock, representing the right to acquire a total of 2,412,878 shares of common stock, was exercised in part (50%) on a cashless basis, resulting in the net issuance of 1,126,814 shares of common stock.

	Effective September 26, 2014, a warrant issued on April 17, 2014 in conjunction with the Private Placement of the Series G Preferred Stock, representing the right to acquire a total of 1,400,000 shares of common stock, was exercised in full on a cashless basis, resulting in the net issuance of 1,326,080 shares of common stock.

	Increase in Authorized Common Shares

	The holders of the Series G Preferred Stock approved and adopted an amendment to increase the number of authorized shares of the Company to 1,405,000,000, 1,400,000,000 of which are shares of common stock and 5,000,000 of which are shares of preferred stock. The Company also sought, and on April 17, 2014 obtained by written consent, sufficient votes of the holders of its common stock, voting as a separate class, to effect the amendment. A certificate of Amendment to the Company’s Certificate of Incorporation to effect the increase in the authorized shares was filed with the Secretary of State of the State of Delaware on April 17, 2014.

	2014 Equity, Equity-Linked and Equity Derivative Incentive Plan

	In connection with the Private Placement, effective March 18, 2014, the stockholders of the Company holding a majority of the votes to be cast on the issue approved the adoption of the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “Plan”), which had been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant of options and restricted stock with respect to up to 105,633,002 shares of common stock, in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company.

	Awards to Officers and Directors as Compensation

	On April 14, 2014, the Board of Directors of the Company awarded a total of 57,000,000 shares of common stock of the Company, including awards of 15,000,000 shares to each of the Company’s three executive officers, who are also directors of the Company, and 12,000,000 shares to certain other parties, one of whom is an associated person of Aurora Capital LLC. These awards were made under the Plan and were awarded to those individuals on that date as compensation for services rendered through March 31, 2014. None of the officers or directors of the Company had received any cash compensation from the Company since joining the Company in March and April 2013, and there were no prior compensation arrangements with such individuals. The fair value of these stock awards will be charged to operations as stock-based compensation in the three months ended June 30, 2014.

	On July 17, 2014, the Board of Directors of the Company awarded stock options to purchase a total of 15,000,000 shares of common stock of the Company, consisting of options for 5,000,000 shares to each of the Company’s three executive officers, who are also directors of the Company. The stock options were awarded as compensation for those individuals through December 31, 2014. The awarded stock options vest in three equal installments on July 17, 2014 (at issuance), September 30, 2014, and December 31, 2014, and expire on July 17, 2019. The exercise price of the stock options of $0.05 per share was in excess of the closing market price of a share of the Company’s common stock on the date of issuance. The Company believes and intends that a portion of the stock options awarded qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. The issuance of incentive stock awards is restricted as to amount as set forth in the Plan, and the form of award of the awarded stock options reflects this intention and the limits under the Plan.

In connection with the appointment of James Sapirstein and Kathryn MacFarlane as directors of the Company on September 3, 2014, the Board of Directors awarded an aggregate of 4,000,000 shares of common stock of the Company to the new directors, consisting of 2,000,000 shares to each new director, vesting 50% upon appointment to the Board of Directors, 25% on September 30, 2014 and 25% on December 31, 2014.

All of these awards were made under the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan.

Debt Settlements

During the three months ended March 31, 2014, the Company executed settlement agreements with four former executives that resulted in the settlement of potential claims totaling approximately $1,336,000 for a total of approximately $118,000 in cash, plus the issuance of options to purchase 4,300,000 shares of common stock exercisable at $0.04 per share for periods ranging from five to ten years. In addition to other provisions, the settlement agreements included mutual releases.

During the three months ended June 30, 2014, the Company also executed settlement agreements with certain former service providers that resulted in the settlement of potential claims totaling approximately $591,000 for a cost of approximately $155,000 in cash, plus the issuance of options to purchase 1,250,000 shares of common stock exercisable at $0.04 per share for a period of five years. In addition to other provisions, the settlement agreements included mutual releases.

The aforementioned agreements resulted in the settlement of potential claims totaling approximately $1,927,000 for a cost of approximately $273,000 in cash, plus the issuance of options to purchase 5,550,000 shares of common stock exercisable at $0.04 per share for periods ranging from five to ten years. The Company continues to explore ways to reduce its indebtedness, and might in the future enter additional settlements of potential claims, including, without limitation, those by other former executives or third party creditors.

University of Illinois 2014 Exclusive License Agreement

On June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to the License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including (i) the payment by the Company of a $25,000 licensing fee, (ii) the payment by the Company of certain outstanding patent costs (not to exceed $16,000), and (iii) the assignment to the University of Illinois of certain rights the Company holds in certain patent applications. In exchange for certain milestone and royalty payments, the 2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea.

Settlement with the Institute for the Study of Aging

On September 2, 2014, the Company entered into a Release Agreement (the “Release Agreement”) with the Institute for the Study of Aging (the “Institute”) to settle an outstanding promissory note, dated May 30, 2000, issued by the Company in favor of the Institute for the principal amount of $247,300 (the “Note”), which was made pursuant to an Agreement to Accept Conditions of Loan Support, also dated May 30, 2000 (the “Loan Support Agreement”). At August 31, 2014, the amount owed under the Note, including accrued interest was approximately $337,000. Pursuant to the terms of the Release Agreement, the Institute received 1,000,000 restricted shares of the Company’s common stock as settlement of all obligations of the Company under the Note and the Loan Support Agreement. Such common shares are “restricted securities” as defined under Rule 144 promulgated under the Securities Act of 1933, as amended, and are not subject to any registration rights. The Release Agreement also includes a mutual release between the Company and the Institute, releasing each party from all claims up until the date of the Release Agreement.

Appointment of New Directors

On September 3, 2014, James Sapirstein and Kathryn MacFarlane were appointed as new directors of the Company. These two new directors are considered to be independent directors. In connection with those appointments and in conformity with its corporate policy of indemnifying all directors and officers, the Board of Directors also agreed at that time to enter into indemnification agreements for all directors and officers of the Company, namely, each existing director of the Company, Arnold S. Lippa, Jeff E. Margolis, and Robert N. Weingarten, each of whom is also an officer of the Company, and with the two new directors. Pursuant to the indemnity agreements, the Company will indemnify each director or officer when such individual is a party or threatened to become a party, by virtue of being a director or officer of the Company, from the costs and expenses, fines and certain other amounts in connection with certain proceedings, including proceedings in the right of the Company, so long as such director or officer acted in good faith and reasonably believed that such actions were not in the best interests of the Company.

Appointment of Chairman of the Company’s Scientific Advisory Board

On September 18, 2014, John Greer, Ph.D. was appointed to the position of Chairman of the Company’s Scientific Advisory Board, which is currently being formed. Dr. Greer is the Director of the Neuroscience and Mental Health Institute at the University of Alberta. He holds two grants regarding research into neuromuscular control of breathing and is the inventor on the use patents licensed by the Company with respect to ampakines. Dr. Greer is expected to assist the Company in forming the rest of its Scientific Advisory Board.

In connection with the appointment of Dr. Greer as Chairman of the Company’s Scientific Advisory Board on September 18, 2014, the Board of Directors awarded 2,000,000 shares of common stock of the Company to Dr. Greer (through his wholly-owned consulting company, Progress Scientific, Inc.), vesting 25% upon appointment, 25% on September 30, 2014, 25% on December 31, 2014, and 25% on March 31, 2015. This award was made under the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan.

Appointment of Senior Vice President of Research and Development

Richard Purcell was appointed as the Company’s Senior Vice President of Research and Development effective October 15, 2014. Mr. Purcell’s commitment to the Company is for 30 hours per week in order to allow him to comply with his previous professional commitments. Mr. Purcell provides his services to the Company through his consulting firm, DNA Healthlink, Inc., with which the Company has contracted for his services.

National Institute on Drug Abuse Grant

On September 18, 2014, the Company entered into a contract with the National Institute on Drug Abuse, which is a division of the National Institutes of Health. The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of the project is to determine the most useful injectable route of administration for CX1942, the Company’s proprietary, soluble ampakine molecule, a potential rescue medication for drug-induced respiratory depression and lethality. The grant is entitled “Novel Treatment of Drug-Induced Respiratory Depression” and is valued at $148,583, which is to be paid in increments over the expected six-month duration of the study which commenced in October 2014. The study will measure the potency, latency to onset and duration of action of CX1942 administered to rats. The Company anticipates that the data obtained from the study will be used to finalize preclinical studies in preparation for initiating Phase 1 clinical studies. The preclinical studies will be performed in collaboration with Dr. David Fuller of the University of Florida and Dr. John Greer of the University of Alberta.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation

	The accompanying condensed consolidated financial statements include the financial statements of Cortex and Pier, its wholly-owned subsidiary, from its August 10, 2012 acquisition date. Intercompany balances and transactions have been eliminated in consolidation.
Cash Concentrations	Cash Concentrations

	The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.
Cash Equivalents	Cash Equivalents

	The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents.
Concentrations of Credit Risk	Concentrations of Credit Risk

	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions.
Fair Value of Financial Instruments	Fair Value of Financial Instruments

	The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

	Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

	Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

	Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

	The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.
Deferred and Capitalized Financing Costs	Deferred and Capitalized Financing Costs

	Costs incurred in connection with ongoing financing activities, including legal and other professional fees, cash finders and placement agent fees, and escrow agent fees, are deferred until the related financing is either completed or abandoned. Costs related to abandoned financings are charged to operations.

	Costs related to completed debt financings are capitalized on the balance sheet and amortized over the term of the related debt agreements. Amortization of these costs is calculated on the straight-line basis, which approximates the effective interest method, and is charged to interest expense in the condensed consolidated statement of operations. Costs related to completed equity financings are charged directly to additional paid-in capital.

	Deferred financing costs, net of accumulated amortization, included in the condensed consolidated balance sheet at September 30, 2013 and December 31, 2012 were $23,301 and $-0-, respectively.
Furniture and Equipment	Furniture and Equipment

	Furniture and equipment are recorded at cost and depreciated on a straight-line basis over the lesser of their estimated useful lives, ranging from three to five years.
Long-Lived Assets	Long-Lived Assets

	The Company reviews its long-lived assets, including intangible assets such as the License Agreement, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually, in conjunction with the preparation of the Company’s fiscal year-end audited financial statements. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company does not have any goodwill.
License Agreement	License Agreement

	The License Agreement with the University of Illinois acquired in the Pier transaction was an acquired intangible asset recorded at cost of $3,411,157 (based on the fair value ascribed to the License Agreement in August 2012, as described in Note 4), and was being amortized on a straight-line basis over the remaining life of its underlying patents of 172 months from the date of acquisition.

	The Company performed an impairment assessment of the carrying value of the License Agreement as of December 31, 2012 and determined that it had no expected future value at that date. The Company made this determination because it was unable to make a $75,000 payment due under the License Agreement at December 31, 2012, as a result of which the License Agreement was forfeited during the three months ended March 31, 2013. The Company recorded an impairment charge to operations of $3,321,678 at December 31, 2012 to write off the carrying value of the License Agreement (see Note 5).
Research Grant Revenues	Research Grant Revenues

	The Company records research grant revenues when the expenses related to the grant projects are incurred. Amounts received under research grants are nonrefundable, regardless of the success of the underlying research, to the extent that such amounts are expended in accordance with the approved grant project.
Stock-Based Compensation	Stock-Based Compensation

	The Company periodically issues common stock and stock options to officers, directors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

	The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.

	Options granted to members of the Company’s Scientific Advisory Board and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.

	The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the security as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair value of common stock is determined by reference to the quoted market price of the Company’s common stock.

	The Company recognizes the fair value of stock-based compensation in general and administrative costs and in research and development costs, as appropriate, in the Company’s statement of operations.

	The Company issues new shares to satisfy stock option exercises.

	There were no stock options issued during the nine months ended September 30, 2013. For options granted during the nine months ended September 30, 2012 the fair value of each option award was estimated using the Black-Scholes option-pricing model using the following input variables: expected life – 10 years; expected volatility – 176%; expected dividend yield - 0%; risk-free interest rate – 0.30%.

	There were no stock options exercised during the nine months ended September 30, 2013 and 2012.
Income Taxes	Income Taxes

	The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

	The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

	Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it projects it will be able to utilize these tax attributes.

	As of September 30, 2013, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.

	The Company is subject to U.S. federal income tax as well as income tax of multiple state tax jurisdictions. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service for the years ending December 31, 2011 through 2013. The Company and its subsidiary’s state income tax returns (prior to the Pier merger) are open to audit under the statute of limitations for the years ended December 31, 2010 through 2013. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

	The Company is currently delinquent with respect to certain of its U.S. federal and applicable states income tax filings and no potential penalties, interest or other charges have been provided for in the Company’s consolidated financial statements because no income was generated during those periods.
Foreign Currency Transactions	Foreign Currency Transactions

	The note payable to related party, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related consolidated statement of operations.
Research and Development Costs	Research and Development Costs

	Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates.

	Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.
Comprehensive Income (Loss)	Comprehensive Income (Loss)

	Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the nine months ended September 30, 2013 and 2012.
Earnings Per Share	Earnings per Share

	The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

	Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.

	At September 30, 2013 and 2012, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

		September 30,
		2013		2012
	Convertible preferred stock		3,679		3,679
	Warrants		5,691,367		22,739,759
	Stock options		5,166,668		17,425,024
	Total		10,861,714		40,168,462
Use of Estimates	Use of Estimates

	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts may differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements

	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-08 (ASU 2014-08), Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under ASU 2014-08, only disposals representing a strategic shift in operations or that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. ASU 2014-08 is effective for annual periods beginning after December 15, 2014. As the Company is engaged in research and development activities, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.

	In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. As the Company does not expect to have any operating revenues for the foreseeable future, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.

	In June 2014, the FASB issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminated the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminated an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statement presentation and disclosures.

	Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.
Reclassifications	Reclassifications

	Certain comparative figures in 2012 have been reclassified to conform to the current year’s presentation. These reclassifications were not material, either individually or in the aggregate.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2013
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At September 30, 2013 and 2012, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

		September 30,
		2013		2012
	Convertible preferred stock		3,679		3,679
	Warrants		5,691,367		22,739,759
	Stock options		5,166,668		17,425,024
	Total		10,861,714		40,168,462

Merger_with_Pier_Pharmaceutica1

Merger with Pier Pharmaceuticals, Inc. (Tables)	9 Months Ended
Merger with Pier Pharmaceuticals, Inc. (Tables)	Sep. 30, 2013
Business Combinations [Abstract]
Summary of Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the fair value of the assets acquired and liabilities assumed by the Company at the closing of the Pier transaction on August 10, 2012.

	Fair value of assets acquired:
	Cash	$	23,208
	Other current assets		698
	Equipment		3,463
	License agreement		3,411,157
	Total assets acquired	$	3,438,526

	Consideration transferred by the Company:
	Fair value of common shares issued	$	3,271,402
	Liabilities assumed		167,124
	Total consideration paid	$	3,438,526
Summary of Pro forma Information Regarding Results of Operations	Pro forma information for the three months and nine months ended September 30, 2012 is summarized as follows:

		Three Months			Nine Months
		Ended			Ended
		30-Sep-12			30-Sep-12
	Total revenues	$	—		$	48,309
	Net loss	$	(731,783	)	$	(2,806,572	)
	Net loss per common share - Basic and diluted	$	(0.01	)	$	(0.02	)
	Weighted average common shares outstanding - Basic and diluted		144,041,556			144,041,556
Summary of Merger-Related Costs	Pier merger-related costs for the year ended December 31, 2012 are summarized as follows:

	Direct merger costs	$	506,876
	Merger-related severance and termination costs		739,231
	Total	$	1,246,107

Notes_Payable_Tables

Notes Payable (Tables)	9 Months Ended
Notes Payable (Tables)	Sep. 30, 2013
Debt Disclosure [Abstract]
Summary of Note Payable	Note payable to Samyang consists of the following at September 30, 2013 and December 31, 2012:

		30-Sep-13		31-Dec-12
	Principal amount of note payable	$	399,774	$	399,774
	Accrued interest payable		61,719		25,340
	Foreign currency transaction adjustment		36,784		40,278
		$	498,277	$	465,392

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2013
Equity [Abstract]
Schedule of Warrants Activity	A summary of warrant activity for the nine months ended September 30, 2013 is presented below.

			Number of				Weighted				Weighted
			Shares				Average				Average
							Exercise Price				Remaining
											Contractual
											Life (in Years)
	Warrants outstanding at December 31, 2012			12,357,884				0.182
	Issued			—				—
	Exercised			—				—
	Expired			(6,666,517	)			0.279
	Warrants outstanding at September 30, 2013			5,691,367			$	0.069				0.53

	Warrants exercisable at December 31, 2012			12,357,884			$	0.182
	Warrants exercisable at September 30, 2013			5,691,367			$	0.069				0.53
Exercise Prices of Common Stock Warrants Outstanding and Exercisable	The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2013:

	Exercise Price				Warrants				Warrants				Expiration Date
					Outstanding				Exercisable
					(Shares)				(Shares)
	$	0.056				4,000,000				4,000,000			25-Jun-14
	$	0.1				1,691,367				1,691,367			October 20, 2013

						5,691,367				5,691,367
Schedule of Stock Options Activity	A summary of stock option activity for the six months ended September 30, 2013 is presented below.

			Number				Weighted				Weighted
			of				Average				Average
			Shares				Exercise				Remaining Contractual
							Price				Life
											(in Years)
	Options outstanding at December 31, 2012			10,754,155				0.557
	Granted			—				—
	Expired			—				—
	Forfeited			(5,587,487	)			1.018
	Options outstanding at September 30, 2013			5,166,668			$	0.06				8.87

	Options exercisable at December 31, 2012			10,754,155			$	0.557
	Options exercisable at September 30, 2013			5,166,668			$	0.06				8.87
Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2013:

	Exercise				Options				Options				Expiration
	Price				Outstanding				Exercisable				Date
					(Shares)				(Shares)
	$	0.06				3,083,334				3,083,334			17-Jul-22
	$	0.06				2,083,334				2,083,334			August 10, 2022

						5,166,668				5,166,668

Organization_and_Business_Oper1

Organization and Business Operations (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Aug. 10, 2012
Patents, extension year			2028
Net loss	$101,165	$1,770,513	$1,118,321	$3,699,290	$7,572,244
Net cash used in operating activities			-163,567	-1,789,792	-1,861,870
Debt principal amount	1,000,000		1,000,000
Private Placement [Member] \| Various Accredited, Non-Affiliated Investors [Member] \| November 5, 2014 [Member]
Sale of convertible notes (with warrants) in private placement	238,500		238,500
Private Placement [Member] \| Various Accredited, Non-Affiliated Investors [Member] \| December 9, 2014 [Member]
Sale of convertible notes (with warrants) in private placement	46,000		46,000
Series G Preferred Stock [Member] \| March And April 2014 [Member]
Sale of preferred stock			928.5
Proceeds from sale of preferred stock			928,500
Pier Pharmaceuticals Inc [Member]
Number of patients				22
Percentage of issued and outstanding of equity securities acquired						100.00%
Dronabinol [Member]
Number of patients					120
Chairman and Chief Executive Officer [Member] \| Series G Preferred Stock [Member]
Proceeds from sale of preferred stock			250,000
June 2013 Through March 2014 [Member] \| Chief Executive Officer [Member]
Short term loans contributed to the company			150,000
June 2013 Through March 2014 [Member] \| Chairman and Chief Executive Officer [Member]
Short term loans contributed to the company			$150,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details Narrative) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Deferred financing costs, net of accumulated amortization	$23,301		$0
Acquired intangible asset	3,411,157
Impairment charge to operations			3,321,678
Stock option issued
Fair value of expected life	10 years
Fair value of expected volatility	176.00%
Fair value of expected dividend yield	0.00%
Fair value of risk-free interest rate	0.30%
Stock options exercised
Minimum percentage of ownership for net operating loss and credit carry forwards to be limited	50.00%
Unrecognized tax benefits related to federal and state income tax
Comprehensive income (loss)	0	0
Payment in default due under License Agreement			$75,000
Patents [Member]
Remaining life of underlying patents	172 months
Furniture and Equipment [Member] \| Minimum [Member]
Furniture and equipment, estimated useful lives	3 years
Furniture [Member] \| Maximum [Member]
Furniture and equipment, estimated useful lives	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share	10,861,714	40,168,462
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	5,166,668	17,425,024
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	5,691,367	22,739,759
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	3,679	3,679

Merger_with_Pier_Pharmaceutica2

Merger with Pier Pharmaceuticals, Inc. (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended	12 Months Ended	0 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Aug. 31, 2012	Dec. 31, 2012	Aug. 10, 2012	Sep. 30, 2014
Number of stock issued for acquisition, value				$3,271,402
Common stock, shares outstanding	144,041,556		144,041,556			144,041,556
Number of option issued during period
Number of option exercisable period			8 years 10 months 13 days
Number of option exercisable price per share	$0.06		$0.06			0.557
Merger transaction costs		-1,084,860		-1,246,107
Number of shares vested fully			5,166,668
Number of shares vested fully, exercise per share			$0.06
Expected dividend yield			0.00%
Due to executive directors	429,231		429,231
Patents [Member]
Remaining life of underlying patents			172 months
Officers And Directors [Member]
Number of option issued during period					7,361,668
Number of option exercisable period					10 years
Number of option exercisable price per share					$0.06
Former Shareholders [Member]
Number of additional shares issued during period						18,300,000
Pier Pharmaceuticals Inc [Member]
Acquisition ownership percentage							100.00%
Number of stock issued for acquisition, Shares							58,417,893
Number of stock issued for acquisition, value							3,271,402
Stock issued during the period, Per share				$0.06			$0.06
Percentage of stock issued by the company							41.00%
Common stock, shares outstanding							144,041,556
Fund entirely granted by a National Institutes of Health							5,000,000
Merger transaction costs						-1,246,107
Fair value of options determined by black scholes pricing model				$310,000
Exercise price per share								$0.06
Stock price per share								$0.06
Expected dividend yield				0.00%
Expected volatility				176.00%
Risk-free interest rate				0.31%
Expected life				10 years
Pier Merger Agreement [Member]
Contingent shares of common stock remained issuable			3,200,000

Merger_with_Pier_Pharmaceutica3

Merger with Pier Pharmaceuticals, Inc. - Summary of Fair Value of Assets Acquired and Liabilities Assumed (Details) (Pier Pharmaceuticals Inc [Member], USD $)	Aug. 10, 2012
Pier Pharmaceuticals Inc [Member]
Cash	$23,208
Other current assets	698
Equipment	3,463
License agreement	3,411,157
Total assets acquired	3,438,526
Fair value of common shares issued	3,271,402
Liabilities assumed	167,124
Total consideration paid	$3,438,526

Merger_with_Pier_Pharmaceutica4

Merger with Pier Pharmaceuticals, Inc. - Summary of Proforma Information Regarding Results of Operations (Details) (Pier Pharmaceuticals Inc [Member], USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Pier Pharmaceuticals Inc [Member]
Total revenues		$48,309
Net Loss	($731,783)	($2,806,572)
Net loss per common share - Basic and diluted	($0.01)	($0.02)
Weighted average common shares outstanding - Basic and diluted	144,041,556	144,041,556

Merger_with_Pier_Pharmaceutica5

Merger with Pier Pharmaceuticals, Inc - Summary of Merger-Related Costs (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Total		$1,084,860		$1,246,107
Pier Pharmaceuticals Inc [Member]
Direct merger costs					506,876
Merger-related severance and termination costs					739,231
Total					$1,246,107

Impairment_and_Termination_of_1

Impairment and Termination of University of Illinois License Agreement (Details Narrative) (University of Illinois [Member], USD $)	0 Months Ended	12 Months Ended
	Mar. 22, 2013	Dec. 31, 2012
University of Illinois [Member]
Payments of milestone fee		$75,000
Milestone fee payment period		30 days
Impairment of license agreement		3,321,678
Milestone fee payable		75,000
Termination of license due to non-payment of milestone fee	$75,000

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	9 Months Ended
Notes Payable (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Oct. 31, 2011	Jul. 31, 2009	Apr. 30, 2009	Sep. 30, 2010	Feb. 28, 2010	Jun. 25, 2012
Stockholder's percentage	20.00%
Accrued note payable interest percentage	12.00%
Maturity date	25-Jun-13
Detachable warrants, term	2 years
Warrants issued to purchase number of common stock	4,000,000
Warrants exercise price per share	$0.06		$0.10	$0.27	$0.34
Call right consideration per share	$0.00
Weighted average closing price per share	$0.08
Warrants expiration date	25-Jun-14
Percentage of proceeds attributed to the debt instrument	64.00%
Amortization of warrants expense percentage	36.00%
Financing costs related to issuance of note payable		$21,370
Payment of accrued interest	102
Dr. Lippa [Member]
Due to officer	40,000
Dr. Lippa [Member] \| March 3, 2014 [Member]
Due to officer	150,000
Percentage of interest rate for due on demand working capital	0.22%
Promissory Note [Member]
Early repayment of promissory note, date		25-Dec-12
Samyang Optics Co Inc [Member]
Warrants exercise price per share						$0.21	$0.27
Samyang Optics Co Inc [Member] \| South Korean Won [Member]
Secured note payable value								465,000,000
Samyang Optics Co Inc [Member] \| US Dollars [Member]
Secured note payable value								$400,000

Notes_Payable_Summary_of_Note_

Notes Payable - Summary of Note Payable (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accrued interest payable	$61,719	$25,340
Total note payable	498,277	465,392
Samyang Optics Co Inc [Member]
Principal amount of note payable	399,774	399,774
Accrued interest payable	61,719	25,340
Foreign currency transaction adjustment	36,784	40,278
Total note payable	$498,277	$465,392

Furniture_Equipment_and_Leasho1

Furniture, Equipment and Leashold Improvements (Details Narrative) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended	12 Months Ended
	14-May-12	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013	Dec. 31, 2012	Mar. 28, 2013	Mar. 23, 2013
Furniture, equipment and leasehold improvements loss				($1,990)
Lease term period	3 years
Office space monthly rate expense	9,204
PPC Irvine Center Investment, LLC [Member]
Termination of lease agreement date						2015-05
Accrued rent								57,535
Furniture, Equipment and Leasehold Improvements [Member]
Disposed furniture, equipment and leasehold improvements					898,731		1,170,849
Security deposit									29,545
Cash				26,000
Furniture, equipment and leasehold improvements loss				$1,990			$39,126

Project_Advance_Details_Narrat

Project Advance (Details Narrative) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2000	Sep. 30, 2013	Dec. 31, 2003	Dec. 31, 2002	Dec. 31, 2012
	Sep. 30, 2000	Sep. 30, 2013	Integer	Integer	Dec. 31, 2012
Conversion price per share		$0.00
Project advance		$333,069			$330,022
Institute for Study of Aging [Member]
Notes payable		337,000
Institute for Study of Aging [Member] \| September 2, 2014 [Member]
Restricted common stock shares issued during period		1,000,000
MCI [Member]
Proceeds from Institute for Study of Aging to fund testing	247,300
Number of patients			175	175
Debt, accrued interest rate		one-half of the prime lending rate
Conversion price per share		$4.50
Project advance		$333,069			$330,022

Stockholders_Equity_Details_Na

Stockholder's Equity (Details Narrative) (USD $)	0 Months Ended	1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended	0 Months Ended		1 Months Ended		0 Months Ended	12 Months Ended
Stockholder's Equity (Details Narrative) (USD $)	Mar. 30, 2006	Aug. 31, 2012	Sep. 30, 2010	Jul. 31, 2009	Apr. 30, 2009	Aug. 31, 2007	Jan. 31, 2007	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2007	Oct. 25, 2006	Aug. 03, 2012	Oct. 31, 2011	Feb. 28, 2010	Jun. 25, 2012	Dec. 31, 2012	Dec. 31, 2011
Preferred stock, shares authorized								5,000,000		5,000,000								1,250,000
Preferred stock, par value								$0.00		$0.00								$0.00
Preferred stock, shares designated								1,250,000		1,250,000								1,250,000
Preferred stock voting										designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred”)	designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred”)
Preferred stock, shares undesignated								3,507,500		3,507,500								3,507,500
Preferred stock, percentage										9.00%	9.00%
Warrants exercise price				$0.27	$0.34			$0.06		$0.06					$0.10
Proceeds from warrant exercises												$443,000
Number of warrants unexercised			4,081,633	6,666,517	7,375,000	3,006,875	2,996,927
Warrants expiration date			expired unexercised in June 2012.	expired in January 2013.	expired in August 2012.	expired in August 2012.	unexercised warrants expired in January 2012.
Warrants exercisable date				31-Jan-13	17-Oct-12
Common stock at an exercise price		$0.06
Fair value of market price per share		$0.60
Option, term	10 years
Vested option term	3 years	10 years
Vested option outstanding		5,166,668
Fair value of options determined		310,000
Option price per share								$0.04		$0.04
Number of option, exercisable								5,166,668		5,166,668								10,754,155
Preferred stock issued upon exercise of warrants										5,691,367
Issuance of stock upon exercise of outstanding stock options										5,166,668
General and administrative expenses								29,575	389,398	893,342	1,715,236
Research and development expenses								28,771	191,874	187,442	659,483
Issuance of share to pier merger										3,239,023
General And Administrative Expense [Member]
General and administrative expenses								0	142,975	0	170,805
Research And Development Expense [Member]
Research and development expenses								0	1,702	0	8,513
1996 Stock Incentive Plan [Member]
Number of shares purchased under the plan													10,213,474
2006 Stock Incentive Plan [Member]
Common stock at an exercise price														$0.06
Fair value of market price per share														$0.06
Number of shares purchased under the plan	9,863,799
Stock option plan description	The exercise price of stock options offered under the 2006 Plan must be at least 100% of the fair market value of the common stock on the date of grant. If the person to whom an incentive stock option is granted is a 10% stockholder of the Company on the date of grant, the exercise price per share shall not be less than 110% of the fair market value on the date of grant.
Percentage of market value equivalents to annual salary	100.00%
Percentage of stock option based upon performance of employees salary	40.00%
Number of shares not exceed limit	50,000
Vested option term														10 years
Vested option outstanding														2,195,000
Fair value of options determined														131,700
2006 Stock Incentive Plan [Member] \| Non Employee Director [Member]
Number of shares purchased under the plan	30,000
Number of shares Additional purchased under the plan	30,000
Percentage of nonqualified options to non-employee directors exercise price equal to fair market value of the common stock	100.00%
Samyang Value Partners Co Ltd [Member]
Number of stock and warrants issued during period															6,765,466
Issuance of warrants to purchase of common stock															1,691,367
Number of warrants unexercised															1,691,367
Warrants expiration date															expired unexercised in October 2013.
Proceeds from issuance of private placements															500,000
Several Institutional Investors [Member]
Number of stock and warrants issued during period						7,075,000	5,021,427
Issuance of warrants to purchase of common stock						2,830,000	3,263,927
Warrants exercise price						2.64	1.66
Warrants exercisable date						28-Aug-12	21-Jan-12
Placement Agents [Member]
Issuance of warrants to purchase of common stock				606,047		176,875										433,824
Warrants exercise price						3.96
Warrants exercisable date						28-Aug-12
Samyang Optics Co Inc [Member]
Issuance of warrants to purchase of common stock			4,081,633														4,000,000
Warrants exercise price			0.206													0.2721
Common stock at an exercise price																	$0.06
Warrants call right consideration price per share																	$0.00
Common stock exceeds price per share																	$0.08
Various Accredited, Non-Affiliated Investors [Member]
Warrants exercise price				$0.37												0.26
Chief Executive Officer [Member] \| 2006 Stock Incentive Plan [Member]
Related parties option to purchase of shares	50,000
March 14, 2014 [Member]
Preferred stock, shares designated								1,700		1,700
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized								37,500		37,500								37,500
Preferred stock, par value								$0.00		$0.00								$0.00
Preferred stock, liquidation preference per share								$0.67		$0.67								$0.67
Preferred stock, shares issued								37,500		37,500								37,500
Preferred stock shares issuable upon conversion, Per share								$0.10		$0.10								$0.10
Effective conversion price per share of common stock								$6.80		$6.80								$6.80
Preferred stock shares issuable upon conversion								3,679		3,679								3,679
Preferred stock redemption amount								$25,001		$25,001								$25,001
Redeemed preferred stock price per share								$0.67		$0.67								$0.67
Number of reserved shares issued upon conversion																		3,679
Preferred stock issued upon exercise of warrants																		12,357,884
Issuance of stock upon exercise of outstanding stock options																		10,754,155
Series A Junior Participating Preferred Stock [Member]
Preferred stock, shares authorized								205,000		205,000
Preferred stock, percentage										9.00%								9.00%
Series B Convertible Preferred Stock [Member]
Preferred stock, percentage																		9.00%
Preferred stock conversion into common stock description																		Each share of Series B Preferred is convertible into approximately 0.09812 shares of common stock at an effective conversion price of $6.795 per share of common stock, subject to adjustment under certain circumstances.	Each share of Series B Preferred is convertible into approximately 0.09812 shares of common stock at an effective conversion price of $6.795 per share of common stock, subject to adjustment under certain circumstances.
Series E Convertible Preferred Stock [Member]
Preferred stock, percentage					0.00%
Series E Convertible Preferred Stock [Member] \| Single Institutional Investor [Member]
Issuance of warrants to purchase of common stock					6,941,176
Series F Convertible Preferred Stock [Member] \| Single Institutional Investor [Member]
Issuance of warrants to purchase of common stock				6,060,470

Stockholders_Equity_Schedule_o

Stockholder's Equity - Schedule of Warrants Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Equity [Abstract]
Number of Warrants, Outstanding, Beginning balance	12,357,884
Number of Warrants, Issued
Number of Warrants, Exercised
Number of Warrants, Expired	-6,666,517
Number of Warrants, Outstanding, Ending balance	5,691,367
Number of Warrants, Outstanding, Exercisable	5,691,367	12,357,884
Weighted Average Exercise Price, Outstanding, Beginning	$0.18
Weighted Average Exercise Price, Issued
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	$0.28
Weighted Average Exercise Price, Outstanding, Ending	$0.07
Weighted Average Exercise Price, Exercisable	$0.07	$0.18
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years)	6 months 11 days
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years)	6 months 11 days

Stockholders_Equity_Exercise_P

Stockholder's Equity - Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Warrants, Outstanding (Shares)	5,691,367	12,357,884
Warrants, Exercisable (Shares)	5,691,367	12,357,884
Warrants [Member]
Warrants, Exercise Price	$0.06
Warrants, Outstanding (Shares)	4,000,000
Warrants, Exercisable (Shares)	4,000,000
Warrants, Expiration Date	6/25/14
Warrant One [Member]
Warrants, Exercise Price	$0.10
Warrants, Outstanding (Shares)	1,691,367
Warrants, Exercisable (Shares)	1,691,367
Warrants, Expiration Date	10/20/13

Stockholders_Equity_Schedule_o1

Stockholder's Equity - Schedule of Stock Options Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Equity [Abstract]
Number of Options, Outstanding, Beginning balance	10,754,155
Number of Options, Granted
Number of Options, Expired
Number of Options, Forfeited	-5,587,487
Number of Options, Outstanding, Ending balance	5,166,668
Number of Options, Exercisable	5,166,668	10,754,155
Weighted Average Exercise Price, Outstanding, Beginning	$0.56
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Forfeited	$1.02
Weighted Average Exercise Price, Outstanding, Ending	$0.06
Weighted Average Exercise Price, Exercisable	$0.06	$0.56
Options Outstanding, Weighted Average Remaining Contractual Life (in Years)	8 years 10 months 13 days
Options Exercisable, Weighted Average Remaining Contractual Life (in Years)	8 years 10 months 13 days

Stockholders_Equity_Exercise_P1

Stockholder's Equity - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Options Outstanding (Shares)	5,166,668	10,754,155
Options Exercisable (Shares)	5,166,668	10,754,155
Stock Option One [Member]
Options Exercise Price	$0.06
Options Outstanding (Shares)	3,083,334
Options Exercisable (Shares)	3,083,334
Options, Expiration Date	17-Jul-22
Stock Option Two [Member]
Options Exercise Price	$0.06
Options Outstanding (Shares)	2,083,334
Options Exercisable (Shares)	2,083,334
Options, Expiration Date	10-Aug-22

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (Aurora Capital Llc [Member], USD $)	0 Months Ended
	Aug. 10, 2012	Mar. 31, 2013
Aurora Capital Llc [Member]
Number of stock issued during period for payment of management fee	2,971,792
Common stock payment fee	$194,950
Reimbursement for legal fees accrued		$85,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	0 Months Ended	9 Months Ended
Commitments and Contingencies (Details Narrative) (USD $)	14-May-12	Sep. 30, 2013	8-May-07
Lease term period	3 years
Office space monthly rate expense	$9,204
Minimum annual royalty payment amount		70,000
Minimum amount to be spent to advance the ampakine compounds		250,000
University of Alberta [Member]
Maintenance payments due and payable			0
Other prospective payments due and payable			$0

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

Sep. 18, 2014

Sep. 30, 2013

Dec. 09, 2014

Sep. 03, 2014

Jul. 17, 2014

Apr. 17, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 02, 2014

Sep. 30, 2014

Dec. 31, 2014

Sep. 30, 2014

Sep. 03, 2014

Sep. 26, 2014

Sep. 05, 2014

Aug. 25, 2014

Sep. 30, 2014

Mar. 18, 2014

Jun. 27, 2014

Nov. 05, 2014

Mar. 14, 2014

Dec. 31, 2012

Apr. 14, 2014

Integer

Preferred stock, shares designated

1,250,000

Preferred stock stated value per share

$0.00

Initial conversion price

$0.00

Sale of stock price per share

$0.04

Common stock shares authorized

205,000,000

Debt instrument, interest rate

12.00%

Debt instrument due date

25-Jun-13

Preferred stock shares authorized

5,000,000

1,250,000

Option exercisable per share

$0.08

Accrued interest

$18

Percentage of awards vesting upon chairman appointment

25.00%

Subsequent Event [Member]

Proceeds from issuance of private placements

46,000

Excess of stock issued

144,041,556

Additional common stock issued

57,000,000

Payment for fee

700

Issuance of warrant

20,000

Exercise price of the stock options

$0.05

Awarded an aggregate shares to directors

4,000,000

Percentage of vesting appointment rate

50.00%

Additional amount paid

591,000

1,336,000

Settlement in cash

155,000

118,000

Issuance of options to purchase common stock shares

1,250,000

4,300,000

Option exercisable per share

$0.04

Option expiration period

5 years

Number of director newly appointed

Subsequent Event [Member] | Release Agreement [Member]

Restricted stock shares

1,000,000

Institute for initial principal amount

247,300

Accrued interest

337,000

Subsequent Event [Member] | Potential Claims [Member]

Additional amount paid

1,927,000

Settlement in cash

273,000

Issuance of options to purchase common stock shares

5,550,000

Option exercisable per share

$0.04

0.04

Subsequent Event [Member] | National Institute on Drug Abuse Grant [Member]

Value of grand agreement

148,583

Subsequent Event [Member] | September 30, 2014 [Member]

Percentage of awards vesting upon chairman appointment

25.00%

Subsequent Event [Member] | December 31, 2014 [Member]

Percentage of awards vesting upon chairman appointment

25.00%

Subsequent Event [Member] | March 31, 2015 [Member]

Percentage of awards vesting upon chairman appointment

25.00%

Subsequent Event [Member] | Board Of Directors [Member]

Additional common stock issued

5,000,000

Number of stock shares awarded

15,000,000

57,000,000

Subsequent Event [Member] | Three Executive Officer [Member]

Number of stock shares awarded

15,000,000

Subsequent Event [Member] | Sapirstein and Katryn Macfarlane [Member]

Awarded an aggregate shares to directors

2,000,000

Percentage of vesting appointment rate

25.00%

Subsequent Event [Member] | Dr. Greer [Member]

Number of stock shares awarded

2,000,000

Subsequent Event [Member] | Series G Preferred Stock [Member]

Private placement representing the acquire number of share

1,400,000

2,412,878

2,112,879

Resulted issuance of common stock

1,326,080

1,126,814

1,942,124

Percentage of exercised cashless basic

50.00%

Subsequent Event [Member] | Maximum [Member]

Option expiration period

10 years

Subsequent Event [Member] | Minimum [Member]

Option expiration period

5 years

Subsequent Event [Member] | 2014 Equity, Equity-Linked And Equity Derivative Incentive Plan [Member]

Restricted stock shares

105,633,002

Subsequent Event [Member] | University Of Illinois 2014 Exclusive License Agreement [Member]

License fee

25,000

Outstanding patent costs

16,000

Subsequent Event [Member] | Private Placement [Member] | Maximum [Member]

Common stock shares authorized

1,405,000,000

Subsequent Event [Member] | Private Placement [Member] | Minimum [Member]

Common stock shares authorized

1,400,000,000

Subsequent Event [Member] | Various Accredited, Non-Affiliated Investors [Member] | Warrant Purchase Agreement [Member]

Initial conversion price

$0.04

Proceeds from issuance of private placements

1,000,000

Additional common stock issued

6,814,286

Debt instrument, principal amount

238,500

Debt instrument, interest rate

10.00%

Debt instrument due date

15-Sep-15

Payment for fee

16,695

Issuance of warrant

477,000

Percentage of common stock share convertible notes

7.00%

Subsequent Event [Member] | Directors And Other Parties [Member]

Number of stock shares awarded

12,000,000

Subsequent Event [Member] | Series G Preferred Stock [Member]

Preferred stock, shares designated

1,700

Preferred stock, designated value

1,000

Percentage of dividend's stated value per share

1.50%

Preferred stock stated value per share

1,000

$1,000

Initial conversion price

0.0033

$0.00

Number of stock shares issued by purchase agreement

303,030

Convertible preferred stock

281,363,634

Preferred stock shares authorized

5,000,000

Subsequent Event [Member] | Series G Preferred Stock [Member] | Purchase Agreement [Member]

Number of stock shares issued by purchase agreement

303,030

Subsequent Event [Member] | Series G Preferred Stock [Member] | Initial Purchasers [Member]

Initial conversion price

0.00396

Number of stock shares issued by purchase agreement

175.28

753.22

Number of stock shares issued amount

175,280

753,220

Proceeds from issuance of private placements

1,500,000

Sale of stock price per share

1,000

Subsequent Event [Member] | Series G Preferred Stock [Member] | Arnold S. Lippa [Member]

Initial conversion price

0.00396

Equity method investments

250,000

Additional common stock issued

250

Subsequent Event [Member] | Series G Preferred Stock [Member] | Initial Tranche [Member]

Initial conversion price

0.00396

Proceeds from initial tranche of private placements

3,955

Percentage of compensation and warrants

5.64%

Percentage of conversion price

120.00%

Warrant exercisable term

5 years

Subsequent Event [Member] | Series G Preferred Stock [Member] | Second Tranche [Member]

Proceeds from initial tranche of private placements

3,465

Percentage of compensation and warrants

12.00%

Percentage of conversion price

120.00%

Warrant exercisable term

5 years

Subsequent Event [Member] | Series G Preferred Stock [Member] | Private Placement [Member]

Initial conversion price

0.00396

Number of stock shares issued by purchase agreement

928.5

Percentage of conversion price

120.00%

Issuance of warrants to purchase of common stock

19,251,271